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Resumo 
 
 A Leucemia Mieloide Crónica (LMC) é uma doença clonal mieloproliferativa 
caracterizada pela existência da translocação t(9:22), da qual resulta o cromossoma Filadélfia. 
Esta translocação dá origem ao gene de fusão BCR-ABL, que codifica a oncoproteina BCR-
ABL com atividade de tirosina cinase aumentada. 
 O Imatinib é um inibidor de tirosina cinase (TKI) que veio alterar a estratégia 
terapêutica habitualmente utilizada em doentes de LMC, o interferão alfa, e é atualmente o 
tratamento de primeira linha na doença. O Imatinib bloqueia especificamente a atividade da 
oncoproteina BCR-ABL e promove uma boa resposta por parte dos doentes. 
 No entanto são conhecidos casos de resistência, sendo a razão mais comum o 
aparecimento de mutações no domínio BCR-ABL que impedem que o Imatinib se ligue com 
sucesso e exerça a sua função. Para além disto, existem outros mecanismos moleculares 
envolvidos na resistência a este fármaco, como a alteração da expressão dos 
transportadores de influxo e efluxo e das enzimas envolvidas na metabolização do fármaco, 
entre outros. 
 Recentemente têm surgido várias terapias que atuam em vias de sinalização celular 
que se têm revelado cada vez com mais de interesse no tratamento da LMC. O Bortezomib, 
um inibidor do proteassoma, o Parthenolide, inibidor do NF-κB, e o Everolimos, inibidor do 
mTOR, são apenas alguns exemplos de novos fármacos que, devido ao seu mecanismo de 
ação podem revelar-se importantes no tratamento de doentes que apresentam resistência 
ao Imatinib. 
 Os microRNAs são pequenas moléculas de ARN não codificante, que regulam a 
expressão génica ao nível pós-transcripcional. Cada vez mais se tem verificado que a 
alteração da expressão dos microRNAs está envolvida em várias patologias, nomeadamente 
no cancro. Alguns microRNAs, como o miR-21, o miR-125b e o miR-155, têm sido 
relacionados com a aquisição de resistência a determinadas terapias em vários tipos de 
neoplasias. 
 Os objetivos deste trabalho foram avaliar a influência dos níveis de expressão dos 
microRNAs, miR-21, miR-125b e miR-155 na sensibilidade e resistência ao Imatinib em linhas 
celulares de LMC, bem como no potencial efeito terapêutico de novos fármacos 
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anticancerígenos dirigidos a alvos moleculares, em particular o Bortezomib, Parthenolide e 
Everolimus. 
 Para atingir estes objetivos utilizámos uma linha celular modelo de LMC sensível ao 
Imatinib, as células K562, e uma linha celular resistente a este TKI obtida a partir da linha 
celular anterior, as células K562 RC. Para avaliar o efeito dos diversos fármacos na 
viabilidade celular recorreu-se ao ensaio metabólico da rezasurina. A morte celular foi 
avaliada por citometria de fluxo com a dupla marcação anexina V e iodeto de protídeo, e 
por microscopia óptica através da coloração May-Grünwald-Giemsa. Alguns dos mecanismos 
envolvidos foram analisados através dos níveis de expressão de BAX e BCL-2, dos níveis 
intracelulares de NF-κB, de conjugados de ubiquitina e de p53 por citometria de fluxo 
recorrendo à marcação com anticorpos monoclonais. Avaliou-se também por western blot 
os níveis de expressão e ativação da proteína AKT, na ausência e na presença dos três 
compostos em estudo de forma a perceber a influência destes compostos nesta via de 
sinalização, devido ao facto de esta via estar relacionada com os mecanismos de ação dos 
três microRNAs em estudo. A avaliação da expressão dos miRNAs efetuou-se por PCR em 
tempo real com recurso a kits comerciais. 
Os ensaios realizados com os fármacos em estudo revelaram que, o Bortezomib, o 
Parthenolide e o Everolimus, em monoterapia, induziram diminuição da viabilidade celular, 
de modo dependente da linha celular, da concentração, do tipo de fármaco e do tempo de 
incubação, induzindo morte celular preferencialmente por apoptose. Assim, nas células 
resistentes ao Imatinib (K562 RC) tratadas com Bortezomib e Parthenolide, observou-se um 
efeito citotóxico mais acentuado do que nas sensíveis, enquanto o Everolimus apresentou 
um efeito mais evidente nas células sensíveis K562 relativamente às células K562 RC. 
 Por outro lado, verificamos aumento da expressão dos miR-21 e miR-125b nas 
células K562 RC em relação as K562. Pelo contrário, os níveis de miR-155 são inferiores nas 
células K562 RC em relação às K562. Estas alterações podem significar que estes miRNAs 
desempenham algum papel na aquisição de resistência ao Imatinib, podendo eventualmente 
constituir novos biomarcadores preditivos de resposta e/ou de monitorização da terapêutica 
com este TKI.  
 Quando as células foram expostas a Bortezomib, Parthenolide e Everolimus, 
verificou-se alteração dos níveis de expressão dos microRNA nas células sensíveis e 
resistentes ao Imatinib. Nas células K562 verificou-se que o tratamento com os três 
compostos em estudo induziu um ligeiro aumento nos níveis de expressão dos miR-21 e 
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miR-155 em relação ao controlo, não se tendo observado nenhuma expressão do miR-125b. 
Por outro lado, nas células K562 RC, observou-se uma ligeira diminuição dos níveis de 
expressão do miR-21 e miR-125b, quando expostos aos três compostos em estudo. No 
entanto, os níveis de expressão do miR-155 apresentaram um ligeiro aumento com a 
exposição ao Bortezomib e ao Parthnolide e um decréscimo com a exposição ao 
Everolimus. 
 Assim, o Bortezomib, Parthenolide e Everolimus poderão constituir uma nova 
abordagem terapêutica em doentes de LMC resistentes à terapêutica com Imatinib, podendo 
os níveis de expressão do miR-21, miR-125b e miR-155 ser indicadores e/ou influenciar a 
resposta à terapêutica. 
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Abstract 
 
 Chronic Myeloid Leukemia (CML) is a clonal, myeloproliferative disorder 
characterized by the existence of the t(9:22) translocation which results in the Philadelphia 
Cromossome. This translocation results in the BCR-ABL fusion gene, which encodes the 
BCR-ABL oncoprotein with enhanced tyrosine-kinase activity.  
 Imatinib is a tyrosine kinase inhibitor (TKI) that modified the therapeutic strategy 
usually used in patients with CML, the interferon alfa, and nowadays is the first line 
treatment in the disease. Imatinib specifically blocks the activity of the BCR-ABL oncoprotein 
and promotes good response by patients. 
 However there are known cases of resistance, the most common reason being the 
onset of mutations in the BCR-ABL gene that prevent Imatinib to bind successfully and 
perform its function. Furthermore, there are other molecular mechanisms involved in 
resistance to this drug, as the altered expression of influx and efflux transporters and of the 
enzymes involved in the metabolism of the drug, among others. 
 Recently several therapies that act in pathways that have become increasingly 
interesting in CML therapy, have emerged. Bortezomib, a proteasome inhibitor, Parthenolide 
an NF-κB inhibitor and Everolimus, an mTOR inhibitor are just a few examples of novel 
therapies that, due to its mechanism of action may prove to be important in the treatment 
of patients who present resistance to Imatinib. 
  MicroRNAs are small noncoding RNA molecules that regulate gene expression at the 
post-trasncripcional level. Increasingly there has been observed that the altered expression 
of microRNAs is involved in several diseases, particularly in cancer. Some microRNAs, such 
as miR-21, miR-125b and miR-155, have been related to the acquisition of resistance to 
certain therapies in various types of malignancies. 
 The aims of this study were to evaluate the influence of the expression levels of miR-
21, miR-125b and miR-155 in the response and resistance to Imatinib in CML cell lines, as 
well as the potencial therapeutic effect of new antineoplasic targeted drugs, particularly 
Bortezomib, Parthenolide and Everolimus. 
 For this, we used a CML cell line sensitive to Imatinib, K562 cells, and a cell line 
resistant to this TKI, obtained from the previous, K562 RC cells. To evaluate the effect of 
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various drugs on cell viability we used the resazurin metabolic assay. Cell death was assessed 
by flow cytometry, with annexin V and propidium iodide double staining and by optical 
microscopy through staining with May-Grünwald-Giemsa. Some of the mechanisms involved 
were analyzed by flow cytometry, trough the expression levels of BAX and BCL-2 and the 
intracellular levels of NF-kB, conjugated ubiquitin and p53, using specific antibodies. AKT 
expression and activation levels were assessed by western blot, in the absence and presence 
of the three compounds in study, in order to understand the influence of these compounds 
in this signaling pathway, due to the fact that this pathway is related with the mechanisms of 
action of the three miRNAs in study. Evaluation of the expression of miRNAs was 
performed by real-time PCR using the commercially available kits. 
 The assays performed with the drugs in study revealed that Bortezomib, Parthenolide 
and Everolimus, in monotherapy, induced decrease of cell viability, in time, dose, drug and 
cell line dependent manner, inducing death preferably by apoptosis. Therefore, cells resistant 
to Imatinib (K562 RC) treated with Bortezomib and Parthenolide presented a cytotoxic 
effect more pronounced than in sensitive cells, while Everolimus showed a less pronounced 
effect in K562 RC cells than in K562 cells. 
 Additionally, we observed increased expression of miR-21 and miR-125b in K562 RC 
cells compared to K562 cells. By contrast, the levels of miR-155 decreased in K562 RC 
relative to K562. These changes might mean that these miRNAs play some role in the 
acquisition of resistance to Imatinib, and may eventually constitute new biomarkers 
predictive of response and / or monitoring of therapy with this TKI. Upon exposure to 
Bortezomib, Parthenolide and Everolimus it was observed an alteration in the expression 
levels of the microRNAs in Imatinib-sensitive and resistant cells.  
 In K562 cells it was noted that treatment with the three compounds in study induced 
a slightly increase in the expression levels of miR-21 and miR-155, when compared to 
control, not having been noted any expression of miR-125b. Moreover, in K562 RC cells, it 
was observed a slightly decrease in the expression levels of miR-21 and miR-125b, when 
exposed to the three compounds in study. However, miR-155 expression levels presented a 
slightly increase upon exposure to Bortezomib and Parthenolide, and a decrease with 
Everolimus exposure. 
 Thus, Bortezomib, Parthenolide and Everolimus may constitute a novel therapeutic 
approach to CML patients resistant to treatment with Imatinib, and the expression levels of 
miR-21, miR-125b and miR-155 may be indicators and/or influence the therapeutic response. 
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1.1. Cancer 
 Human cells are regulated by complex mechanisms that allow cellular homeostasis. 
For most of the time, Deoxyribonucleic Acid (DNA) sequences are the most steady, 
unchangeable components of a cell, but nearly all of the other cellular apparatuses are in 
constant flux, being continuously created and recycled (Weinberg, 2007). The mechanisms of 
gene regulation determine which genes will be expressed and when, comprising the most 
robust defenses against the environment. If this complex regulatory circuit is disrupted it can 
lead to accumulation of genetic and epigenetic abnormalities, which result in transformation 
of normal cells into malignant derivatives (Pavet et al., 2011). 
 Cancer can be described as a disease of abnormal gene function. Normal cells stop 
obeying the restraints imposed within differentiated cells and instead proliferate aberrantly 
and eventually turn malignant. Tumorigenesis is a complex, multistep process driven by a 
sequence of randomly occurring mutations and epigenetic alterations of DNA that affect the 
genes controlling cell proliferation, survival, differentiation and other traits associated with a 
malignant cell phenotype (Weinberg, 2007).  
 The danger posed by the disease comes from the combination of two properties: the 
ability of cells to proliferate in an uncontrolled way and their ability to spread through the 
body, invading areas reserved to other cells. Contrary to normal cells, that have a finite 
capacity to replicate, cancer cells can replicate indefinitely (Hayflick, 2003). It is suggested 
that at some point, during tumor progression, premalignant cell populations exhaust their 
amount of allowed doublings and can only continuing tumorigenesis by breaching the 
mortality barrier and acquire unlimited replicative potential (Hanahan and Weinberg, 2000). 
 Normal stem cells have the capacity to self renewal and differentiate into daughter 
cells that become tissue-specific and also have the potential to proliferate extensively. These 
three properties make stem cells unique (Jordan et al., 2006, Lobo et al., 2007). Recent 
studies enlighten the present of stem cells that have the exclusive ability to regenerate 
tumors. These cells are known as cancer stem cells (CSC) (Figure 1). Cancer stem cells are 
self-renewing cells within a tumor that have the exclusive ability to lead the growth and 
spread of an original tumor. Self-renewal enables these cells to produce daughter cancer 
cells that are more differentiated but also lack intrinsic regenerative potential, being destined 
to stop proliferating or die. Stem cells become more susceptible to initial oncogenic 
mutations because they are in constant division and are exposed to more genotoxic stress 
than their shorter-lived, differentiated progeny. (Lobo et al., 2007, O'Brien et al., 2010). 
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Figure 1. Normal and cancer stem cells. Normal stem cells have the ability to grow and differentiate 
into progenitor and mature cell populations, respectively. The figure show normal stem cells 
capacities: self-renewing (red curved arrow), differentiation into progenitors with multilineage 
potential (cells of different colors) having extensive proliferative capacity. Mutations can occur in 
normal stem cells and through this way cancer stem cells arise. Like normal stem cells, cancer stem 
cells can self-renew and have the ability to proliferate extensively forming new tumors (adapted from 
Jordan, 2006). 
 
 An important goal in cancer therapy is the development of treatments that target 
stem cells, once that, if these cells are not eradicated, the tumor may regrow and relapse 
(Figure 2). 
 
Figure 2. Development of effective anticancer therapies. Cancer stem cells (CSCs) are biologically 
distinct from bulk tumor cells. Current treatments for cancer can considerably diminish tumor 
burden, but have a decreased effect on CSCs, which are later capable of driving tumor recurrence 
and regrowth. To achieve cancer remission or cure, therefore, it will be necessary to develop novel 
therapies that target CSCs (adapted from Dick, 2008). 
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1.2. Hematopoietic System 
 Hematopoiesis in vertebrates is maintained during an organism’s lifetime due to a 
strict regulation of the highly hierarchical hematopoietic system. Because mature blood cells 
have a very short life span, hematopoietic stem cells (HSCs) are required through life to 
maintain and continuously regenerate the entire blood supply, which is constantly being 
replaced. Hematopoietic stem cells, as all other stem cells, are capable of self-renewal – the 
production of additional HSCs – and differentiation, specifically into specialized blood cells 
that have important function in control homeostasis balance and response to 
microorganisms and inflammation (Hoffman and Calvi, 2014). HSCs reside within the bone 
marrow and depend on their microenvironment, the niche, for regulation of appropriate 
stem cell behavior. Within the microenvironment, HSC receive internal and external signals, 
which direct them to preserve balance between self-renewal and production of progeny to 
maintain hematopoiesis, while at the same time maintain a HSCs pool. Disruption of these 
signals can lead to stem cell depletion, altered hematopoiesis and malignancy (Hoffman and 
Calvi, 2014, Lo Celso and Scadden, 2011). 
 The process of formation of hematopoietic stem cells begins with the HSC that gives 
origin to another HSC by self-renewal and to multipotent progenitors (MPPs) which lose 
self-renewal potential but remain fully differentiates into all multilineages. The MPPs further 
give rise to common myeloid progenitors (CMPs) and common lymphoid progenitors 
(CLPs). These progenitors differentiate into their restricted lineage commitment, according 
to the present stimulus: CMPs progress to erythrocytes, megakaryocytes (which give rise to 
platelets) and myeloblasts (which give rise to granulocytes and monocytes). CLPs advance to 
T Lymphocytes, B Lymphocytes and Natural Killer cells (Figure 3) (Chotinantakul and 
Leeanansaksiri, 2012). 
Hematopoiesis is also supported by marrow space that contains also stromal cells 
which produce cytokines/growth factors, such as c-KIT ligand (among others), that stimulate 
stem cells and progenitors. Cytokines, including interleukins, thrombopoietin (Tpo), and 
erythropoietin (Epo), also influence progenitor function and survival (Orkin and Zon, 2008). 
All this growth factors activate several signaling pathways that stimulated hematopoietic cell 
proliferation, differentiation and death.  
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Figure 3. Normal Hematopoiesis. Hematopoietic Stem Cells self renewal and also give arise to 
commom progenitors of myeloid and lymphoid lineage. These cells will differentiate into the different 
blood elements (adapted fromhttp://www.biolegend.com/cell_markers). 
 
1.3 Chronic Myeloid Leukemia 
 Chronic Myeloid Leukaemia (CML) is a clonal, myeloproliferative disorder 
characterized by the neoplasic transformation of hematopoietic stem cells. It was the first 
neoplastic disease associated with a chromosomal aberration, known as the Philadelphia 
chromosome (Figure 4). This chromosome is the result of a reciprocal translocation that 
lead to the juxtaposition of the breakpoint cluster region (BCR) gene on chromosome 22 
and Abelson murine leukemia (ABL) gene on chromosome 9. This results in a fusion gene, 
the BCR-ABL gene, which codes BCR-ABL transcripts and fusion oncoproteins with unusual 
tyrosine kinase activity. The BCR-ABL transcript has constitutively tyrosine-kinase activity 
resulting in the activation of signaling pathways involving a cascade of proteins that control 
the cell cycle, confer a proliferative advantage, decreased adherence of the leukemic cells to 
the bone marrow stroma and also genomic instability, making the cell more susceptible to 
developing further genetic abnormalities (Hehlmann et al., 2007). 
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Figure 4. Philadelphia Chromosome. Translocation of chromosomes 9 and 22 at bands 9q34 and 
22q11.2, respectively, results in the formation of Philadelphia Chromosome.  The juxtaposition of the 
ABL oncogene from 9q34 and the BCR locus from 22q11.2 results in a chimeric gene on the 
derivative chromosome 22 (adapted from Armand, 2007). 
 
 1.3.1 Chronic Myeloid Leukemia Treatment  
 Chronic Myeloid Leukemia was the first to be treated with a biologic agent, the 
Interferon Alfa (IFN-α) (Alves, 2011). INF-α was the first effective therapy for CML. This 
agent remained the treatment of choice for CML patients, until a shift in therapeutic strategy 
after the arrival of the tyrosine kinase  inhibitor, Imatinib (Frazer et al., 2007). 
  CML was the first neoplasm for which knowledge of the genotype led to a rationally 
designed targeted therapy. Although, in recent years new tyrosine-kinase inhibitors (TKIs) 
such as Dasatinib or Nilotinib have emerged, allogenic stem cell transplantation is the only 
curative therapy for CML (Hehlmann et al., 2007). 
 
 1.3.1.1. Imatinib 
 Imatinib is a small-molecule drug that targets and inhibits the BCR-ABL tyrosine 
kinase by competitive binding at the ATP-binding site, making the target protein inactive. 
Imatinib produces a sustained cytogenetic response in the majority of patients and it is 
clinically well tolerated (Frazer et al., 2007). Despite its remarkable efficacy in treating CML, 
it does not have the capacity to eradicate residual disease related with the persistence of 
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stem cells, which are known to be resistant to Imatinb. Even in patients with undetectable 
BCR-ABL transcripts, relapses are seen after interruption of Imatinib, suggesting that the 
treatment has to be maintained indefinitely. 
 Resistance to Imatinib results most of the times of the development of mutations in 
the BCR-ABL kinase domain, thus preventing Imatinib binding successfully. Other 
mechanisms involve over expression of BCR-ABL; acquired clonal evolution, on account of 
addition of novel chromosomal aberrations, and mechanisms related with pharmacological 
mechanisms of drug transportation, resulting in the reduction in the quantity of available 
unbound Imatinib, culminating in suboptimal levels of Imatinib to achieve the desired effect 
(Frazer et al., 2007, Hehlmann et al.). 
 
 1.3.1.2. Novel therapies 
 To try to improve clinical response by patients and overcome resistance to Imatinib, 
novel therapies have emerged. Alternative therapeutic approaches may involve an attempt to 
obtain a synergistic effect through combination of BCR-ABL TKIs with inhibitors of  
non-BCR-ABL targets or targets found in chronically activated signaling pathways 
downstream of BCR-ABL (Melo and Chuah, 2008). 
 Proteasome inhibition has been an area of interest in CML therapy.  
The ubiquitin-proteasome pathway is responsible for the degradation of several cellular 
proteins. Proteasomes have a dual role of ‘‘housekeeping” (disposing of damaged proteins) 
and regulation (degrading proteins involved in cell cycle regulation and tumor growth) within 
the cell. This latter property has driven the investigation of proteasome inhibitors as a new 
cancer therapy (Frazer et al., 2007).  
 Inhibition of transcription activated by Nuclear Factor-κB (NF-κB) has been 
implicated as the mechanism responsible for the antitumor effect of proteasome inhibitors 
(Melo and Chuah, 2008). Bortezomib (PS341, Velcade) is a potent and selective proteasome 
inhibitor that has clinical activity in multiple myeloma and possibly lymphoproliferative 
disorders (Cortes et al., 2004, Sarmento-Ribeiro et al., 2005). It has shown to decrease 
proliferation, induce G2/M phase cell cycle arrest and promotes apoptosis in Imatinib 
sensitive and resistant CML cell lines. Despite simultaneous treatment of Imatinib sensitive 
CML cell lines with Bortezomib and Imatinib promoted and antagonistic interaction on 
growth inhibition, the sequential exposure to Bortezomib followed by Imatinib resulted in a 
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synergistic proapoptotic effect in Imatinib sensitive cells (Gatto et al., 2003, Melo and Chuah, 
2008).  
 In the same way that Bortezomib’s NF-κB inhibition can be used to increase the 
response of cancer cells to chemotherapy, Parthenolide, a potent inhibitor of NF-κB, can 
also be used for the same effect. The mechanism of NF-κB down-regulation by Parthenolide 
appears to occur via inhibition of the Iκ B Kinase (IκK) complex. Parthenolide has shown to 
induce very effectively leukemic stem cells-specific cell death in vitro in acute myeloid 
leukemia (AML) (Guzman et al., 2005). 
 BCR-ABL fusion protein also activates the PI3K/AKT/mTOR pathway (Alves, 2011). 
Mammalian target of Rapamycin (mTOR) is a serine-threonine kinase downstream of 
Phosphoinositide 3 kinase (PI3K) that is activated upon phosphorylation by Protein Kinase B 
(AKT). Everolimus, a derivate of rapamycin, is an inhibitor of mTOR (Melo and Chuah, 
2008). It has been show that Everolimus revokes mTOR late re-activation in response to 
Imatinib (Mancini, M. et al., 2010), an activation that is possibly responsible for the 
development of an Imatinib resistance phenotype (Melo and Chuah, 2008). 
 
1.4. Epignetics  
 When Conrad Waddington first introduced the word “epigenetics” in the early 
1940s, the term was used to explain “the casual interaction between genes and their 
products, which bring the phenotype into being” (Esteller, 2008). But, currently epigenetics 
refers specifically to the study of heritable changes in gene expression that do not involve 
any alteration in the DNA sequence. The disruption of such changes results in a wide variety 
of pathologies, including cancer (Rodriguez-Paredes and Esteller, 2011). It is known these 
non-genetic alternations are regulated by three major epigenetic modifications: DNA 
methylation, histone modifications (histone code) and miRNAs. 
 
 1.4.1. DNA methylation 
 In humans, DNA methylation takes place predominantly at the carbon-5 of a cytosine 
positioned within a 5’-CpG-3’ dinucleotide resulting in methyl-CpG. Methylation is carried 
out by DNA methyltransferases (DNMTs) with S-adenosyl-methionine (SAM) as the methyl 
donor (Kristensen et al., 2009) (Figure 5). 
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Figure 5. Schematic representation of DNA methylation. Cytosine is converted to 5’methyl-cytosine 
via the actions of DNA methyltransferase (DNMT). DNA methylation typically occurs at cytosines 
that are followed by a guanine (adapted from Zakhari, 2013). 
 
 There are three main DNA methyltransferases (DNMTs) that play major roles in 
establishing and maintaining DNA methylation patterns: DNMT1, which maintains the 
existing methylation patterns following DNA replication during S-phase, and DNMT3A and 
DNMT3B, enzymes responsible for de novo methylation that target previously unmethylated 
CpGs (Rodriguez-Paredes and Esteller, 2011). Transcription can be directly repressed by 
CpG methylation, preventing methylation-sensitive transcriptions factors from biding to their 
recognition sites. Methylated CpGs can also bind methyl-CpG-binding proteins through the 
methyl-biding domain (MBD), cutting off the binding sites of methylation-insensitive 
transcription factors and averting transcription, in addiction to recruiting repressive 
chromatin remodeling complexes (Rouhi et al., 2008). CpG dinucleotides sites are not 
randomly distributed in the human genome; instead they are concentrated either in short 
CpG-rich DNA regions known as CpG islands, which are located in approximately 60% of 
human gene promoters, or in regions of large repetitive sequences such as centromeres and 
transposable elements (Rodriguez-Paredes and Esteller, 2011). Albeit in the latter case most 
of the CpGs are methylated to avoid chromosome instability and inappropriate transcription 
of repetitive elements leading to insertional mutagenesis, the majority of CpG islands are 
usually unmethylated in normal cells, and the associated genes are actively transcribed 
(Kristensen et al., 2009) (Figure 6).  
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 It is thought that CpG islands escape methylation by binding of transcription factors 
and hence maintain their CpG density (Rouhi et al., 2008). 
 
  
 
Figure 6. DNA methylation patterns in normal 
cells.  DNA methylation can occur in different 
regions of the genome. (a) In normal cells, 
methylation of repetitive sequences prevents 
genomic instability and spurious transcription 
initiation, as aberrant transcription can occur 
from incorrect transcription start sites (TSSs). 
(b) and (c) CpG islands at promoter sites are 
usually unmethylated, allowing transcription. 
(d) CpGs located in gene bodies frequently 
are methylated in normal cells, preventing 
false transcriptions (adapted from Varela-Rey 
et al., 2013). 
 
 However there are exceptions to this general trend as for instance in genomic 
imprinting where only genes from one of the two parental alleles are expressed. 
Hypermethylation of one allele results in its silencing and leads to monoallelic expression 
(Rodriguez-Paredes and Esteller, 2011). Genomic imprinting requires DNA hypermethylation 
at one of the two parental alleles of a gene to ensure monoallelic expression (Esteller, 2008). 
Other exceptions include hypermethylation of genes during X-chromosome inactivation in 
females and germ-line genes such as the MAGE (melanoma antigen gene) genes, which are 
hypermethylated and silence in almost all tissues except malignant tumors. (Kristensen et al., 
2009). 
 Besides DNA methylation, epigenetic activation or silencing is also accomplished 
through histone modifications (Rouhi et al., 2008). 
 
 1.4.2. Histone Modifications 
 The principal structure of eukaryotic chromatin is the core nucleosome, consisting of 
an octomer of histones (two each of  H2A, H2B, H3 and H4) around which the DNA winds 
(Kristensen et al., 2009). Chromatin not only serves as a way to condense DNA within the 
cellular nucleus, but also as a way to stabilize and control how the DNA is used.  
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 In a simplified view chromatin can exist in two basic states: an open, transcriptionally 
competent euchromatin and a closed, more condensed and transcriptionally silent 
heterochromatin (Guil and Esteller, 2009). 
 Histones can undergo multiple post-transcriptional modifications such as acetylation, 
methylation, phosphorylation and ubiquitination that mainly occur at specific residues located 
predominantly but not exclusively in N-terminal tails. These modifications affect gene 
transcription and DNA repair. The most studied modifications are histone 
acetylation/deacetylation and methylation/demethylation (Figure 7). 
 
Figure 7. Histone modifications. Amino acids 
available for chemical modification in terminal 
tails of core histones are shown here. The 
modifications include acetylation of many 
different lysine residues, methylation of 
arginine and lysine residues, and 
phosphorylation. Modifications are made or 
removed by enzymes specialized for a 
particular modification (adapted from 
https://promega.files.wordpress.com/2014/01/
histones_11340ta.jpg). 
  
Histone acetylation of lysine (K) residues is associated with open chromatin and 
active transcription (Figure 8.A.), whereas the functional consequences of the methylation of 
histones on chromatin compaction and state of transcription depends on the type of residue 
– lysine or arginine – and the specific site that the methylation modifies (e.g. K4, K9 or K20) 
as well as the number of methyl groups covalently bound to the residue. Hence, methylation 
of H3 at K4 is related to transcriptional activation while methylation of H3 at K9 or K27 and 
of H4 at K20 is associated with transcriptional repression (Figure 8.B.) (Esteller, 2008, Rouhi 
et al., 2008).  
 A given locus may contain both transcription-promoting and repressive marks and 
the state of transcriptional activation is determinate by the balance of these marks. It has 
been proposed that distinct histone modifications form a “histone code” and that exert their 
effect on chromatin as a collective (Rouhi et al., 2008). 
 The histones-modifying enzymes most well characterized are: acetyl trasnferases 
(HATs), that add acetyl groups on lysine residues, and deacetylases (HDACs and sirtuins), 
that remove them, and also histone methyl transferases (HMTs) that add methyl groups on 
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lysine residues or on arginine residues and demethylases (HDTs) that reverse that process 
(Hatziapostolou and Iliopoulos, 2011). 
 Histone-modifying enzymes and methylated DNA interact. For instance, MBD 
proteins recruit to CpG-methylated loci nuclear corepressor complexes, such as SIN3 
complex that contains histone deacetylases that remove acetyl groups from lysine residues 
present in the N-terminus of histones. This creates a more compact chromatin structure 
which is not accessible to the transcriptional machinery.  In this way DNA methylation can 
directly and indirectly lead to the transcriptional repression of genes (Rouhi et al., 2008). On 
the other hand, the histones bound to unmethylated promoters are acetylated by HATs, 
which contribute to an open chromatin structure sheltering actively transcribed genes 
(Kristensen et al., 2009). Notably, all epigenetic processes work together to establish and 
maintain the global and local condensed or descondensed chromatin states that eventually 
determine gene expression (Rodriguez-Paredes and Esteller, 2011). 
 
 
Figure 8. Histone acetylation (A) and Methylation (B). In (A) closed chromatin prevents transcription 
factors involved in gene expression to get to DNA, and gene expression does not occurs. Histone 
deacetylases (HDACs) are enzymes that remove the acetyl groups from histones, resulting in less 
accessible chromatin structure. There are also histone acetyltransferases (HATs) that add an acetyl 
group to histones, resulting in an open chromatin structure that allows gene transcription (adapted 
from Nicole A., 2013). In (B) (1.) methylation of H3 at K4 is related to transcriptional activation and 
conversely, its demethylation accompanies gene repression. In contrast in (B) (2.), methylation of H3 
at K9 is associated with transcriptional repression; hence removal of H3K9 methyl marks coincides 
with gene activation (Wysocka et al., 2005). 
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 The aberrant functions of chromatin modifying enzymes, which can result in altered 
histone modification or DNA methylation patterns, are hallmarks of human diseases (Guil 
and Esteller, 2009). 
 
1.5 Epigenetics and cancer 
 The occurrence of epigenetic alterations in cancer was discovered about 25 years 
ago with the demonstration of genome-wide DNA hypomethylation in tumors as compared 
with the level of DNA methylation in their normal-tissue counterparts (Rouhi et al., 2008). 
 The loss of methylation may contribute to tumorigenesis by inducing chromosomal 
instability, re-activation of transposable elements, loss of imprinting, as in the case of the 
IGF2 gene (encoding insulin-like growth factor 2) in Wilms’ tumor and colorectal cancer 
(Rodriguez-Paredes and Esteller, 2011, Wilson et al., 2007). Besides that, can contribute to 
the activation of normally methylated oncogenes such as PAX2 (a gene that encodes a 
transcription factor involved in cell proliferation and other important activities) (Esteller, 
2008, Kristensen et al., 2009). The degree of hypomethylation increases through the 
evolution of a tumor, from a benign lesion to an invasive cancer. Nonetheless, it is not clear 
how important DNA hypomethylation is in tumorigenesis. Possibly it is only a real causative 
factor in some cancers and a modulator of cancer risk in others (Kristensen et al., 2009). 
 However, the most recognized epigenetic disruption in human tumors is the CpG 
island promoter hypermethylation associated with silencing of tumor suppressor genes 
(Figure 9) (Rodriguez-Paredes and Esteller, 2011). 
 The first tumor suppressor gene reported to undergo silencing as a result of 
promoter methylation was the Retinoblastoma gene (RB) gene in retinoblastoma tumors, 
followed by other important tumor suppressor genes, such as MLH1 in colon cancer, 
BRCA1 in breast cancer and MGMT in glioblastomas (Kristensen et al., 2009). The 
transcriptional inactivation caused by promoter hypermethylation affects genes involved in 
the main cellular pathways: DNA repair, Rat Sarcoma (RAS) signaling, cell cycle control, p53 
network, cell-to-cell interaction and angiogenesis, among others (Portela and Esteller, 2010). 
Hypermethylation occurs at different stages in the development of cancer and in different 
cellular networks and the hypermethylation patterns in tumor suppressor genes are specific 
to a certain cancer type, as seen, for instance, by the exclusivity of BRCA1 hypermethylation 
in breast and ovarian neoplasias (Ballestar and Esteller, 2005, Esteller, 2008). 
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Figure 9. Aberrant DNA methylation profile in cancer cells. In normal cells, nearly all of the CpG 
dinucleotides are methylated, whereas CpG islands are unmethylated. In cancer cell, a global loss of 
DNA methylation at repeated sequences leading to global hypomethylation of the genome is 
observed along with DNA hypermethylation at specific sites, such as tumor suppressor genes 
promoters, inducing the silencing of their associated genes (adapted from Moison C, 2013). 
 
 Disruption of normal patterns of covalent histone modification is another hallmark of 
cancer. One of the most characteristic examples is the loss of acetylation at lysine 16 and 
tri-methylation at lysine 20 of histone H4, in association with hypomethylated repetitive 
DNA sequences present in many primary tumors (Figure 11). They have been found in 
breast and liver cancer (Hatziapostolou and Iliopoulos, 2011, Rodriguez-Paredes and Esteller, 
2011). Silencing of tumor suppressor genes in cancer cells has been associated with a 
particular combination of histone marks: deacetylation of histones H3 e H4, loss of H3K4 
trimethylation (active mark) and gain of H3K9 methylation and H327 trimethylation 
(repressive marks – silenced chromatin). The presence of hypo-acetylated and 
hypermethylated histones H3 and H4 silences certain genes with tumor suppressor like 
properties, despite the absence of hypermethylation of the CpG island (Figure 10) (Esteller, 
2008). 
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Figure 10. Histone modification paterns in normal and cancer cells. The Figure shows  the main 
modifications of the four core histones in normal cells (type and position in the amino acid 
sequence). Additionally, and because disruption of their normal patterns is related to cancer, histone 
modifications typically associated with disease have been highlighted (adapted from Rodriguez-
Paredes and Esteller, 2011).  
 
 The loss of acetylating is mediated by HDASs, which have been found overexpressed 
or mutated in different tumor types. Sirtuin family of proteins is the main class of HDACs 
implicated in this process. Sirtuin 1 (SIRT1) deacetylase activity and gene expression is 
upregulated in a wide variety of tumors and SIRT1 also interacts with DNMT1, affecting 
DNA methylation patterns as well. Several cancer types (e.g., colon, uterus, lung and 
leukemia) also bear translocations leading to the formation of aberrant fusion proteins, 
mutations or deletions in HATs and HAT-related genes, contributing this way to the global 
imbalance of histone acetylation (Portela and Esteller, 2010).  
 Cancer cells exhibit altered distribution of the histone methyl marks mainly due to 
the aberrant expression of both histone methyltransferases (HMT) and histone demethylases 
(HDMs). The histone methyltransferase EZH2 – which is the H3K27 specific HMT – 
enhances proliferation and neoplastic transformation and is overexpressed in several cancer 
types such as breast, colon and lung cancer. Recent discoveries also show inactivating 
mutations of EZH2 in follicular and diffuse large B cell lymphomas (Rodriguez-Paredes and 
Esteller, 2011). In addition to its histone methyltransferase activity, EZH2 interacts with 
DNMTs directly controlling DNA methylation (Portela and Esteller, 2010). 
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1.6 MicroRNAs 
 A vast diversity of RNAs expressed in the genome has diversified functions, other 
than being only the “messengers” from DNA to protein expression. These RNAs, named 
non-coding-RNAS (ncRNAs), were previously assumed to be “trash” but now are starting to 
be classified and carefully studied. Among these ncRNAs, microRNAs (miRNAs or miRs) 
have stood out (Teixeira, 2013). 
 The first miRNA, lin-4, was described in Caenorhabditis elegans in 1993 by Victor 
Ambros and his co-workers Rosalind Lee and Rhonda Feinbaum. Lin-4, a 22 nucleotide RNA 
product of the LIN-4 gene, was shown to target lin-14 mRNA and negatively regulate the 
level of lin-14 protein (Lee et al., 1993). This appeared to be unique until a second example 
of a similar small regulatory RNA in C. elegans, let-7, was discovered seven years later by 
Gary Ruvkun’s lab (Piriyapongsa et al., 2007, Reinhart et al., 2000). 
 Since 2001, when the term miRNA was used for the first time, a great progress has 
been made in understanding the role of miRNAs and it has been demonstrated that miRNAs 
are involved in many biological processes including differentiation, proliferation and 
apoptosis (Vasilatou et al., 2010). 
 
 1.6.1 MicroRNAs’ biogenesis 
 MicroRNAs are small (19-24 nucleotides) single-stranded RNA molecules that 
negatively regulate gene expression at post-transcriptional level. The result is the 
degradation or inhibition of translation of their target mRNAs (Tuccoli et al., 2006).  
 The miRNAs have a standard biogenesis that consists of three phases: transcription, 
maturation and assembly (Teixeira, 2013) (Figure 11). The biosynthesis of miRNAs starts in 
the nucleus with the transcription of long double stranded RNA molecules known as 
primary-microRNAs (pri-miRNA) by RNA polymerse II. These pri-miRNAs are 
characterized by a stem-loop structure and while still in the nucleus are cleaved into 
precursor RNA (pre-miRNA), a 70-100 nucleotide hairpin-shaped structure, by Drosha, an 
RNase III enzyme, and its interacting partner DGCR8. DGCR8 stabilizes Drosha and unlike 
the last can directly and stably interact with pri-miRNAs. Pre-miRNAs are exported to 
cytoplasm by exportin-5, and there occurs the next processing step. In the cytoplasm the 
loop of the pre-miRNAs is cleaved by Dicer (another RNse III enzyme) in association with 
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HIV-1 TAR RNA binding protein (TRBP), an essential RNA-binding protein and Protein 
ACTivator of the Interferon-induced protein kinase (PACT) (in humans) and pre-miRNAs 
are processed into a 19-24 nucleotide miRNA duplex (Vasilatou et al., 2010). After Dicer-
mediated cleavage, Dicer and its interactors TRBP or PACT dissociate to from the miRNA 
duplex (Winter et al., 2009). To form the active RNA induced silencing complex (RISC) that 
performs gene silencing, the double stranded miRNA is separated by a RNA helicase and the 
mature strand is loaded together with Argonaute (Ago) protein into the RISC, while the 
passenger strand is degraded.  
 The strand that remains stably bound to RISC represents the mature miRNA and is 
thought to be the one whose 5’ end is thermodynamically more unstable, thus becoming 
more easily unwounded by the helicase (Teixeira, 2013). MiRNA loaded RISC recognizes 3’- 
Untranslated Region (UTR) regions of mRNAs and if there is full complementary between 
miRNA and mRNA degradation occurs, while partial complementarily causes translational 
repression. The miRNAs bind to the target transcript by their nucleotides 2-8, counted to 
the 5’ end, which are called the “miRNA seed” (Figure 11) (Teixeira, 2013, Tuccoli et al., 
2006, Vasilatou et al., 2010). This post-transcriptional inhibitory mechanism is of critical 
importance in fundamental cell processes, including development, proliferation, survival and 
death (Vasilatou et al., 2010). 
 
Figure 11. MicroRNA biogenesis. RNA polymerase II or III transcribes miRNA genes, generating long 
primary transcripts (pri-miRNAs) that are cleaved by the microprocessor complex Drosha-DGCR8 
in the nucleus. The resulting precursor hairpin, the pre-miRNA, is exported by Exportin 5-Ran-GTP 
to the nucleus.  
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In the citoplasma, pre-miRNA is processed into mature miRNA by Dicer in a complex with double-
stranded RNA-binding protein TRBP. The functional strand of mature miRNA is loaded together 
with Argonaute (Ago2) proteins into RISC (RNA-induced silencing complex). Once incorporated 
into RISC, the miRNA guides it to silence the target genes by degradation of the mRNA through 
direct cleavage, by inhibiting protein synthesis or by mRNA deadenylation (adapted from Winter et 
al.,2009). 
 
 1.6.2. Regulation of gene expression by miRNAs 
 The mechanism by which miRNAs regulate gene expression is still under 
investigation. Each miRNA can have one or more target mRNA while each mRNA may be 
regulated by one or more miRNAs (Vasilatou et al., 2010). The great complexity of miRNA-
mediated regulation relies on their ability to cooperate: various miRNAs can bind to the 
same mRNA and thereby regulate together the expression of a single mRNA, providing a 
stronger translational inhibition. Additionally, while some miRNA regulate the expression of 
various genes simultaneously others regulate specific individual targets. Many miRNAs are 
expressed in a tissue-specific or developmental-stage-specific manner. It comes out clear that 
miRNAs expression must be tightly regulated, because it has to be restricted to a particular 
development stage or cell type (Tuccoli et al., 2006). Growing evidence suggests that 
miRNAs can be regulated at the levels of miRNA promoter transcription, methylation, 
miRNA processing, RNA editing and miRNA-target interactions (Breving and Esquela-
Kerscher, 2010). Various studies have shown that miRNAs aberrant expression is associated 
with various pathological conditions including a wide variety of diseases broadening from 
diabetes, to cardiovascular or to various types of cancers (Teixeira, 2013). 
 
 1.6.3. Epigenetic control of miRNA expression 
 Compared to miRNA biogenesis that has been intensively studied and is well 
described, much less is known about the regulation of miRNAs expression. Genes encoding 
miRNAs are as tightly regulated as any other gene in the genome and in this way miRNAs 
expression is also submitted to similar epigenetic regulation. Epigenetic regulation of protein-
coding genes can affect the expression of miRNAs as many of them are located in introns of 
protein coding genes and are regulated  by the promoter of the host  gene (Singh and 
Campbell, 2013). Approximately half of the human promoter regions contain CpG-rich 
regions, so it is not surprising that the expression of miRNAs can be affected by promoter 
hypermethylation or global hypomethylation (Figure 12) (Rouhi et al., 2008).  
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Figure 12. Epigenetic control mechanisms of miRNAs expression. (A) CpG island regulates 
transcription of an intergenic miRNA. (B) CpG island regulates transcription of a gene which hosts a 
miRNA. (C) CpGs regulate the transcriptional start site belonging to an intronic miRNA. (D) A 
transcription site recruits DNA and histone modifying enzymes to epigenetically regulate a miRNA 
within a gene which is surrounded by CpGs (adapted from Rouhi et al.,2008). 
 
 However methylation is not the only epigenetic mechanism that can affect miRNAs 
expression. Scott and collaborators (Scott et al., 2006) showed that histone deacetylase 
inhibition is followed by extensive and rapid alteration of miRNAs levels (Iorio and Croce, 
2012). In normal breast tissues, miR-155 was proposed to be epigenetically repressed by the 
wild-type BRCA1, which interacted with HDAC2 to deacetylate H2A and H3 on the  
miR-155 promoter. Nonetheless, the loss or mutation of BRCA1, resulted in miR-155 
upregulation, as HDAC2 could not be recruited to the miR-155 promoter (Liu et al., 2013).  
 
 1.6.4. MicroRNA control of epigenetic mechanisms 
 MicroRNAs can also control the epigenetic machinery including DNA methylation 
and histone modifications by regulating the expression of important epigenetic modifiers 
involved in the methylation or acetylation of DNA and histones.  
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 These miRNAs are called “epi-miRNAs”, and their aberrant expression is often 
related to development or progression of human cancer. First evidence of the existence of 
these epi-miRNAs was the discovery that miR-29 family is able to directly target the de novo 
DNA methyltransferases DNMT-3A and 3B in lung cancer. More recently, maintenance 
DNA methyltrasnfersase DNMT1 was also associated, although indirectly, through 
regulation of the transactivator Sp1. Introduction of miR-29s into lung cancers and AMLs 
resulted in reactivation of silenced tumor suppressor genes and inhibition of carcinogenesis 
(Iorio et al., 2010). MiR-101 is another miRNA with tumor suppressive properties linked to 
epigenetic machinery, reported to be down-regulated in different tumor types. As recently 
shown (Friedman et al., 2009), miR-101 is able to directly modulate EZH2 expression, which 
mediates epigenetic gene silencing by trimethyling histone H3 lysine 27 (H3K27me3) and is 
involved in silencing tumor suppressor genes in cancer. Transfection of miR-101 in bladder 
cancer cell lines and stable knockdown of EZH2 created a similar suppressive phenotype. 
The loss of miR-101 and consequent overexpression of EZH2 seems to alter the global 
chromatin structure in cancer. Enzymes regulating histone acetylation may also be directly 
regulated by epi-miRNAs, such as HDAC4, which is  a direct target of miR-1 and miR-140 
and HDAC1 regulation is mediated by miR-449a (Iorio et al., 2010). 
 MicroRNAs can be considered part of a multilevel regulatory mechanism involved in 
modulation of gene expression. They are able to silence specific target molecules at post-
transcriptional level, including members of the epigenetic machinery and are also strictly 
regulated by epigenetic events such as DNA methylation and histone modifications. An 
altered balance of the components of this network may lead to pathological conditions such 
as cancer (Iorio et al., 2010). 
 
1.7. Cancer and microRNAs 
 The first direct link between miRNAs and cancer was made by Carlo Croce and 
colleagues in 2002, describing that miR-15a and miR-16a, located on chromosome 13q14, 
are frequently deleted and/or down-regulated in patients with B cell chronic lymphocytic 
leukemia (B-CLL) (Calin et al., 2002). This result provided the first evidence that miRNAs 
could be involved in the pathogenesis of human cancer as the deletion of chromosome 
13q14 caused the loss of these two miRNAs (Calin et al, 2002). Indeed, study of a large 
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collection of chronic lymphocytic leukemias (CLLs) showed knock down or knock out of 
miR-15a and miR-16-1 in approximately 69% of CLL patients (Iorio and Croce, 2012). 
 This discovery triggered the investigation of the chromosomal location of miRNAs. 
Interestingly another study of Calin et al. (2004) showed that many human miRNAs genes 
are frequently located at fragile sites as well in genomic regions associated with cancer, 
suggesting that miRNAs are involved in the development of human cancer (Shenouda and 
Alahari, 2009). 
 There are many mechanisms and biological alterations that underlie the abnormal 
miRNA expression in cancer, including transcriptional deregulation, mutations, DNA copy 
number abnormalities and defects in the miRNA biogenesis machinery. Epigenetic changes 
like DNA methylation and histone modifications are also responsible for aberrant miRNA 
expression. Several miRNAs, such as miR-1, miR124a and Mir-127, are embedded in CpG 
island region and are epigenetically silenced by promoter hypermethylation and histone 
modifications, thus causing them to be under epigenetic control in human cancers 
(Hatziapostolou and Iliopoulos, 2011). In cancer, miRNAs function as regulatory molecules, 
acting as oncogenes (named oncomirs) or tumor suppressors (named tumor suppressors 
miRNAs). Therefore, miRNAs whose expression is increased in cancer and can  
down-regulate tumor suppressors or other genes involved in cell differentiation, conferring 
them an oncogenic role by simulating proliferation, angiogenesis and invasion, these miRNAs 
act as oncomirs. On the other hand, miRNAs whose expression is usually decreased in 
cancer and normally down-regulate different proteins with oncogenic activity act as tumor 
suppressors miRNAs (Figure 13) (Shenouda and Alahari, 2009). However this classification 
needs to be used with caution, as a miRNA can function as an oncomir or a tumor 
suppressor miRNA depending on the cellular context or tissue (Teixeira, 2013). 
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Figure 13. MicroRNAs as oncogenes and tumor suppressor genes. OncomiRNAs are actively 
transcribed in cancer and inhibit tumor suppressor genes, simulating proliferation and invasion. 
Tumor suppressor miRNAs (tsmiRNAs) expression is usually decreased in cancer and contributes to 
increase oncogene translation resulting in increase of angiogenesis and escape cell death. (adapted 
from Iorio and Croce, 2012). 
 
 In a study, Dong Wang and colleagues (Wang et al., 2010) performed a 
comprehensive analysis of putative human miRNAs oncogenes and tumor suppressors. They 
found that oncogene and tumor suppressor miRNAs showed different patterns in function, 
expression, chromosome distribution, transcription factors and targets. Oncomirs were 
more frequently found in amplified regions in human cancers, whereas tumor suppressors 
miRNAs were located mainly in the deleted regions. This indicates that in human cancer 
oncogene miRNAs often gain function, while tumor suppressor miRNAs frequently lose 
function. Oncogene miRNAs tend to cleave target mRNAs more frequently than tumor 
suppressor miRNAs. These results indicate that these two types of cancer-associated 
miRNAs play different roles in cancer formation and development. 
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 1.7.1 MiR-21 
 MiR-21 was one of the first miRNAs detected in the human genome and is frequently 
up-regulated in cancer having the majority of its reported targets as tumor suppressors. It 
has been involved in promoting tumor growth, cell proliferation, inflammation and 
angiogenesis. In particular, miR-21 is strongly involved in apoptosis regulation, being known 
to evade  cell death (Feng et al., 2010). 
 A study by Talotta and colleagues (Talotta et al., 2009) showed that in response to 
RAS signaling, Activator Protein I (AP-1) induces miR-21 expression. MiR-21 induced by AP-
1 triggers the downregulation of both Phosphatase and Tensin Homolog (PTEN) and 
Programmed Cell Death 4 (PDCD4), in response to the RAS oncoprotein. PDCD4, in turn, 
is necessary for the maximal stimulation of AP-1 activity in response to RAS signaling. Both, 
PTEN and PDCD4 dowregulation dependent of RAS is predominantly mediated by miR-21. 
The results point to miR-21 as a target and a regulator of AP-1, because it is at the same 
time controlled by AP-1 and necessary for the maximal induction of AP-1 activity in RAS-
transformed cells (Figure 14). 
 
Figure 14. Scheme of the functional interactions between AP-1, miR-21 and PDCD4 in RAS 
dependent tumorigenesis. RRE indicates the AP-1-regulated RAS-responsive-enhancer of miR-21 
promoter. X, Y, Z... indicates the many unidentified miR-21 target transcripts (adapted from Talotta 
et al.,2009). 
 
 PDCD4 has also been reported to be a mediator of Lipopolysaccharides (LPS)-
induced apoptosis. The results presented by Sheedy et al. (2010), established that after LPS 
stimulation, PDCD4 induces apoptosis by inducing IL-6 and NF-κB. Besides inducing 
apoptosis NF-κB also induces miR-21 expression, by a process that requires MyD88 and NF-
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κB subunit p65, since bone-marrow-derived macrophages (BMDMs) lacking MyD88 and 
mouse embryonic fibroblasts deficient in p65 failed to induce miR-21 in response to LPS.  
NF-κB by inducing miR-21 expression inhibits PDCD4 translation, what would lead to 
decrease of NF-κB activity, creating a negative feed-back loop. PDCD4 protein expression 
also decreases by a process that involves proteasome-dependent protein degradation, 
mediated by AKT/mTOR signaling (Young et al., 2010). PDCD4 and miR-21 provide key 
links between inflammation and oncogenesis. 
 In the case of PTEN, miR-21 downregulation of this gene leads to increase activity of 
AKT and reduces apoptosis in cancer. PTEN inhibits AKT pathway by reversing the 
phosphorylation of PI3K. PTEN inhibits the activation of NF-κB. AKT is known to promote 
the NF-κB pathway, so miR-21 overexpression would result in increased NF-κB activation 
(Figure 15) (Choudhury and Li, 2012). 
 
Figure 15. MiR-21 enhances the NF-κB signaling pathway. MiR-21 downregulates PTEN, a negative 
regulator of the PI3K/AKT pathway that elevates NF-κB activation, promoting in this way NF-κB 
activity (adapted from Choudhury and Li, 2012). 
 
 Recent studies have shown that miR-21 is overexpressed in various types of cancer 
and contributes to tumor resistance to chemotherapy. One of those studies by Haitao Bai 
and colleagues (Bai et al., 2011) demonstrates that resistance of the chemotherapeutic agent 
Daunorubicin (DNR) in K562 cell leukemic line is related to upregulation of miR-21 
expression. MiR-21 may regulate survival of leukemia cell lines by downregulating PTEN 
expression and activating the PI3K/AKT pathway. The involvement of PDCD4 in DNR-
induced resistance in K562 cells was also accessed. This group found that overexpression of 
miR-21 in K562 cells or knockdown of miR-21 in K562/DNR cells did not influence PDCD4 
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protein levels, suggesting that the later is not involved in drug resistance to DNR in this cell 
line. 
 1.7.2. MiR-125b 
 MiR-125b is a homologue of Caenorhabditis elegans miRNA lin-4, being one of the 
most conserved miRNAs. It can behave as either a tumor suppressor or an oncogenic 
miRNA, depending on the context (Tili et al., 2012). 
 It has been reported that miR-125b expression decreases shortly after LPS 
stimulation of RAW264.7 macrophages, implying that it might have anti-inflammatory effects. 
The primary transcript that produces miR-125b is controlled in part by the AKT pathway 
(Androulidaki et al., 2009, O'Connell et al., 2011), which is activated by LPS (Figure 16). In 
contrast, miR-155 expression is increased by LPS and attending to the proinflammatory 
environment present in near 25% of tumors, the concurrent up-regulation of miR-155 and 
down-regulation of miR-125b can be involved in the onset of some neoplasias (Tili et al., 
2012). 
 Beyond these examples, there is evidence that miR-125b directly targets and 
 down-regulates proapoptotic factors, such as BCL2 homologous Antagonist/Killer (BAK1), 
BCL2 Modifying Factor (BMF) and lin28 (Figure 16) (O'Connell et al., 2011). Le et al. (2009) 
also demonstrated that miR-125b is a negative regulator of p53 in humans, suppressing 
apoptosis. Bousquet and colleagues (Bousquet et al., 2010) showed that overexpression of 
miR-125b is able to accelerate the tumorigenicity of the BCR-ABL fusion protein and to 
confer a proliferative advantage to BCR-ABL leukemic cells. They also showed that  
miR-125b is able to induce primary lymphoid or myeloid leukemia in mice. Other studies 
also established a relation between miR-125b overexpression and fusion proteins such as the 
TEL-AML1 fusion protein in acute lymphocytic leukemia (ALL) patients and the translocation 
PML-RARA in pediatric AML (Bousquet et al., 2010). 
 MiR-125b has been reported to contribute to tumor resistance to chemotherapy. 
Overexpression of miR-125b was showed to induce resistance in K562, THP-1 and Jurkat 
cells to the drug DNR by reducing apoptosis, while the suppression of miR-125b was found 
to enhance DNR cytotoxicity in REH cells. Furthermore, it was observed that miR-125b 
mediated DNR resistance in leukemia cell lines through decreasing expression of G protein-
coupled receptor kinase 2 (GRK2) and p53-upregulated modulator of apoptosis (PUMA), 
which were shown to be direct targets of miR-125b (Zhou et al., 2014).  
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 Interestingly, miR-125b was found to confer resistance to Paclitaxel in breast cancer 
cells and to Cislatin in ovarian cancer cells, through the same mechanism: by targeting pro-
apoptotic BCL-2 antagonist killer 1, and suppressing its expression (Kong et al., 2011, Zhou 
et al., 2010). 
 
Figure 16. MiR-125b functions. MiR-125b transcription is controlled by the AKT pathway. Important 
targets of mir-125b include lin28, BAK1 and BMF, which are important in cell survival and apoptosis 
(adapted from O’Connel et al., 2011).   
 
 1.7.3. MiR-155 
 MiR-155 was one of the first miRNAs identified in the hematopoietic system due to 
its high expression levels in certain types of lymphomas (O'Connell et al., 2011). MiR-155 is a 
product of B-cell integration cluster (BIC) transcript. The presence of the double-stranded 
fold-back motif on BIC RNA would later be recognized as the precursor hairpin encoding 
miR-155, showing that this miRNA was produced from BIC transcripts. In matter of fact, 
miR-155 is only found in cells expressing BIC transcripts. The only evolutionarily conserved 
sequence of the BIC gene is the hairpin from which miR-155 is processed, suggesting that 
BIC oncogenic functions are through miR-155. In humans, both miR-155 and BIC transcript 
levels are elevated in different malignancies such as diffuse large B cell lymphoma (DL-BCL), 
Hodgkin lymphoma, B-CLL and also acute myelomonocytic leukemia. Besides hematological 
malignancies, miR-155 was described to be up-regulated in solid tumors such as breast, 
colon and lung cancers (Teng and Papavasiliou, 2009, Tili et al., 2009). MiR-155 is expressed 
at low levels in most hematopoietic cells, under steady-state conditions, with basal 
expression higher in hematopoietic stem and progenitor cells  (HSPCs) when compared with 
other more mature bone marrow lineages (O'Connell et al., 2011). 
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 The oncogenic properties of miR-155 are associated to its capacity to enhance 
cellular proliferation and its inhibition of apoptosis through down-repression of caspase-3 
activity and also the targeting of FADD (FAS associated death domain), TP53BP1 (Tumor 
suppressor p53-binding protein 1) and Ikappa B kinase epsilon (IKKepsilon) (Tili et al., 2009). 
 Recent studies (Lee et al., 2012) show that miR-155 is associated with the loss of 
SHIP-1, an enzyme involved in the PI3K/AKT pathway. The BIC transcript regulation is under 
the transcriptional control of NF-κB and AP-1 when myeloid cells are exposed to 
inflammatory stimuli. While these factors increase BIC transcription, BIC transcription levels 
appear to be down-regulated by Signal transducer and activator of transcription 3 (STAT3) 
and AKT (Figure 17) (O'Connell et al., 2011, Tili et al., 2009). Using proteasome inhibitors of 
NF-κB activity, Tili and colleagues (Tili et al., 2007) observed that miR-155 might be at least 
transiently under the direct control of NF-κB transcriptional activity. Overall, NF-κB, under 
particular circumstances, might control the expression of miR-155. 
 
Figure 17. MiR-155 regulation and functions. MiR-155 targets mRNAs encoding SHIP1, SOCS1 and 
other proteins. In turn, SHIP and SOCS1 normally inhibit inflammatory responses that lead to the 
activation of AKT dependent pathways (that inhibit miR-155 transcription) and NF-κB (that up-
regulates miR-155 transcription) (adapted from O’Connell et al., 2011). 
 
 MiR-155 has been associated to drug-resistance in osteossarcoma (Chen et al., 2014) 
and to inhibition of the sensitivity of lung cancer cells to the therapeutic agent Cisplatin 
(Zang et al., 2012). 
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 In conclusion, in this continuously changing field, there have been numerous 
discoveries that have allowed uncovering the miRNAs functions in the most diverse areas, 
including myeloid biology. Because they act on the pre-existing mRNA, miRNAs functions 
are highly dependent in a lot of factors, such as the cell type in which are induced (O'Connell 
et al., 2011). MicroRNAs represent a new layer of genetic regulation in the central dogma of 
molecular biology (DNA-mRNA-protein) (Rouhi et al., 2008). Understanding the regulatory 
mechanisms of the miRNA pathway will allow the development of new biomarkers and 
therapeutic strategies based on the target genes of the miRNA that will enable treating 
diseases such as cancer through the regulation of oncogenic or tumor suppressor pathways 
in human patients (Breving and Esquela-Kerscher, 2010) and also help to prevent resistance 
to chemotherapeutic drugs by identifying the patients more suitable for a certain therapy. 
 However, the role of miRNAs in CML, in particular in monitoring therapy response, 
in resistance to TKI and how to circumvent it is not totally clarified. 
Aims: 
What we pretend with this work is: 
 To evaluate the expression levels of miRNAs (miR-21, miR-125b and miR-155) in 
K562 cells (a model of CML in vitro) sensitive and resistant to Imatinib.  
 To evaluate the therapeutic potential of Bortezomib, Parthenolide and Everolimus in 
K562 cells sensitive and resistant to Imatinib. 
 See how Bortezomib, Parthenolide and Everolimus modulate miRNAs expression 
levels and correlate them with the response to therapy. 
 
Expected results: 
 
 We hope to contribute to clarify the role of these miRNAs in the response to 
Imatinib, namely in Imatinib resistance, and to new targeted drugs, that translated to clinical 
practice could be used as new prognostic biomarkers to predict and monitoring drug 
response in CML patients. 
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Abstract 
 Imatinib (IMA), the first specific inhibitor of the tyrosine kinase BCR-ABL1, is at 
present, the first-choice treatment for patients Chronic Myeloid Leukemia (CML). Despite 
the good results obtained, some patients show primary resistance or relapse after an initial 
response (secondary or acquired resistance). In an attempt to respond to IMA resistance, 
novel therapies have emerged aiming to improve patients clinical response and overcome 
resistance to IMA. Recent studies have shown that microRNAs (miRNAs) altered expression 
may be involved in several types of cancer and may also contribute to tumor resistance to 
chemotherapy. However, their role in IMA resistance and in the efficacy of new drugs in 
circumventing this resistance is not well known.  
 In this study, we investigated the basal expression levels of miR-21, miR-125b and 
miR-155 in an IMA sensitive CML cell line, the K562 cells, and in a derivative cell line 
resistant to IMA therapy, the K562 RC cells. We also evaluated whether Bortezomib, 
Parthenolide and Everolimus mediated a cytotoxic effect in these cell lines and how these 
drugs modulated the miRNAs expression levels.  
 Our results show d that miR-21 and miR-125b were upregulated in the IMA resistant 
cell line K562 RC compared to its parental line K562. Upon exposure to the compounds we 
verified that expression levels were altered from K562 cells to K562 RC cells, with the 
decrease in the expression of miR-21 and 125b upon exposure to all compounds. Everolimus 
reduced expression levels in miR-155 contrary to the other compounds. We can 
hypothesize that the compounds in study present themselves as alternatives in the 
therapeutic approach in patients with CML resistant to IMA therapy. Additionally, miRNAs 
expression levels in CML patients could be used has biomarkers to predict an evaluated the 
response to IMA therapy or to select the better drug to the right patient. 
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1.Introduction 
 
 Chronic Myeloid Leukemia (CML) is a myeloproliferative disorder characterized by a 
chromosomal translocation, known as the Philadelphia chromosome. The result of this 
translocation is a fusion gene, the BCR-ABL, which encodes a fusion oncoprotein with 
unusual tyrosine kinase activity (Hehlmann et al., 2007). This oncoprotein was the starting 
point for the development of Imatinb, the first line therapy of CML, a specific tyrosine 
kynase inhibitor that targets and inhibits the BCR-ABL tyrosine kinase activity (Frazer et al., 
2007). However, drug resistance is considered to be a multifactorial phenomenon that 
involves several major mechanisms. Resistance to Imatinib has been associated with 
mutations in the BCR-ABL kinase domain, reduced apoptosis, changes in drug metabolism, 
and in membrane drug transporters (increase in efflux or decrease in influx) (Alves, 2011).  
 MicroRNAs (miRNAs) are small, non-coding RNAs that act post-transcriptionally and 
negatively regulate the expression of target genes by binding to the 3′UTR of mRNA. If 
complementary between miRNA and mRNA is complete, degradation occurs, while partial 
complementary only causes translational repression, decreasing the proteins levels they 
encode (Tuccoli et al., 2006). This post-transcriptional inhibitory mechanism is of critical 
importance in fundamental cell processes, including development, proliferation, survival and 
death (Vasilatou et al., 2010). 
 In particular, miR-21, miR-125b and miR-155 have shown to have influence in 
oncogenesis and drug resistance (Bai et al., 2011, Chen et al., 2014, Zhou et al., 2010). MiR-
21 and miR-155 are frequently upregulated in cancer (Buscaglia and Li, 2011, Tili et al., 2009) 
while miR-125b can behave either as a tumor suppressor or as an oncogenic miRNA, 
depending on the context (Tili et al., 2012). All these three miRNAs are in some way 
involved with PI3K/AKT pathway, because they regulate some of its components, and/or are 
regulated by  them (Choudhury and Li, 2012, O'Connell et al., 2011). Recently, miRNAs 
have been related to resistance to Imatinib (Firatligil et al., 2013, Li et al., 2013). 
 Additionally, to try to improve patient’s clinical response and overcome Imatinib 
resistance, novel therapies have emerged. Bortezomib, Parthelonide and Everolimus are 
therapeutic agents that act at different levels in ubiquitin-proteasome and PI3K/AKT 
pathways. Bortezomib is proteasome inhibitor (Cortes et al., 2004), Parthenolide is a NF-κB 
inhibitor that acts through inhibition of IκK complex (Guzman et al., 2005) and Everolimus is 
an inhibitor of mTOR (Melo and Chuah, 2008). 
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 In this work, we evaluated the expression of miR-21, miR-125b and miR-155 in cell 
lines sensitive and resistant to Imatinib. In the same cell lines we also examined the 
therapeutic potential of novel therapies as Bortezomib, Parthenolide and Everolimus. 
Moreover, we correlate the levels of miRNAs with the response to these novel 
therapeutics.  
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2. Materials and Methods  
 2.1. Cell culture 
 The K562 cells, a Chronic Myeloid Leukemia cell line, established from the bone 
marrow of a 53 years old female patient with Chronic Myeloid Leukemia in blast crises, was 
purchased at American Type Culture Collection (ATCC). The cell line was routinely grown 
in Roswell Park Memorial Institute 1640 (RPMI1640) medium (L-glutamine 2 mM, HEPES-Na 
25 mM, NaHCO 1.5 g/L, penicillin 100 U/mL and streptomicyn 100 µg/mL), supplemented 
with 10% heat-inactivated fetal bovine serum (FBS) (Gibco, Invitrogen), at 37ºC and with 5% 
CO2 in an humidified incubator. The K562 cells were always seeded at an initial density of 
0.5 million cells/mL (106 cel/mL). 
 The Imatinib resistant cell line, named K562 RC, was established in our lab after 
gradual and continued exposition to Imatinib,and maintained in culture under the same 
conditions of K562 cell line, but supplemented with 250 nM of Imatinib. The IC50 of Imatinib 
in this resistant cell line is 8 times higher than in K562 cells. 
 
 2.2. Incubation of the CML cell lines with antineoplasic drugs 
 The K562 and K562 RC cells were maintained in culture as described in the 1.1 
section in the absence and presence of antineoplasic drugs: proteasome inhibitor – 
Bortezomib (BTZ) (5 nM to 100 nM); IκK inhibitor – Parthenolide (PTL) (1 µM to 20 µM) 
and mTOR inhibitor – Everolimus (EVE) (5 µM to 50 µM). All the studies were performed 
with an initial density of 0.5x106 cel/mL, during a period of 72 hours. 
 
 2.3. Evaluation of cellular viability with resazurin metabolic assay 
 Cell viability was assessed by the resazurin assay. Briefly, rezasurin is a non-
fluorescence blue compound (oxidated form) that penetrates the cells and acts as an 
electron acceptor. The oxidation-reduction reaction originates a pink fluorescent 
compound, resofurin. This color alteration is the result of the cellular metabolism and 
represents an indicator of cell viability and proliferation (Zhang et al., 2004).  
 At each 24h, resazurin was added at final concentration of 10 µg/mL. The absorbance 
was analyzed at 570 nm (correspondent to the oxidated form) and at 600 nm 
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(correspondent to reduced form), being the difference between them a measurement of cell 
viability. The results represent the mean ± standard deviation (SD) of 3 to 6 independent 
experiences.  
 
 2.4 MicroRNAs quantification by q-RT-PCR 
 To evaluate microRNAs expression we used TaqMan MicroRNA Assays from 
Applied Biossystems. It is constituted by two steps: first we synthesize a cDNA chain from a 
specific primer of the microRNA with help of a reverse transcriptase (RT), and then occur 
an amplification of the sequence correspondent to a specific microRNA for every RT-PCR 
reaction. In the cDNA synthesis, we used a specific primer of RT-PCR, miRNA from 
TaqMan MicroRNA assays (Applied Biossystems) and reagents from TaqMan MicroRNA 
Reverse Transcription Kit. After the cDNA synthesis, we proceeded to the amplification of 
miR-21, miR-125b, miR-155 and RNU6B (endogenous control) by q-RT-PCR. For each 
miRNA, we used one TaqMan MicroRNA Assay with specific probes and primers. The 
miRNA quantification was determined in untreated cells and in cells exposed to 2.5 nM of 
BTZ, 5 µM of PTL and 5 µM of EVE for 48h.  
 
 2.5. Cell death evaluation 
 For all conditions tested, the cell death analysis was performed by optical 
microscopy, through morphological assessment of May-Grünwald-Giemsa stained slides, and 
by flow cytometry, using the Annexin V (AV) and Propidium Iodide (PI) double staining.  
 For the morphological evaluation, the cells were transferred to slides and fixed with 
FBS, stained and evaluated under light microscopy, using a Zeiss Axioskop2 equipped with 
Zeiss Axiocam ICc3. The images acquired were processed by Zeiss program.  
 The Annexin V and PI double staining allow the discrimination between live cells (AV-
/PI-), early apoptotic cells (AV+/PI-), necrotic cells (AV-/PI+) and late apoptotic or necrotic 
cells (AV+/PI+). In resume, in the beginning of apoptosis phosphatidylserine, a phospholipid 
with negative charge, suffers a translocation from the inner side of the membrane to the 
outer side. AV is a molecule able to bind to phospholipids with negative charge in presence 
of calcium. As AV is bind to a fluorochrome, it enables to determine the location of 
phosphatidylserine in the membrane. This way, we can identify cells in early apoptosis. IP is a 
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DNA intercalator molecule that, within DNA chain, emits fluorescence. In early apoptosis 
cell membrane is still intact and IP is not capable to enter the cell and bind to DNA chain. In 
later stages of apoptosis and in necrosis, the nuclear envelope becomes discontinuous 
allowing IP to intercalate with DNA (Goncalves et al., 2013). To perform this flow 
cytometry assay, cells were collected after 48h of treatment, washed with PBS (centrifuged 
at 500 xg for 5 min), resuspended in 100 µl of binding buffer and incubated with 1 µg of AV 
(BD Pharmingen) and 1 µg of IP (BioLegends) for 15 min in the dark. After incubation time, 
cells were diluted in 300 µl of binding buffer and analyzed using a FACScalibur flow 
cytometer. The experiments were performed in triplicated and the result analysis was 
performed using the Paint-a-GateTM program. 
 
 2.6. Assessment of BAX, BCL-2, p53, NF-κB and ubiquitin expression levels  
 The modulation of BAX, BCL-2, p53, NF-κB and ubiquitin conjugated proteins 
expression levels were analyzed in cells cultured in the absence and presence of Bortezomib, 
Parthenolide and Everolimus. Since they are intracellular molecules, it was necessary to fix 
and permeabilize the cellular membrane. Briefly, the cells were fixed using the kit IntraCell 
(ImunnoStep) by incubation with 100 µL of solution A for 15 min. After centrifugation, the 
cells were permeabilized with 100 µL of solution B (kit IntraCell) and incubated with 1 μg of 
anti-BAX (PE), 1 μg of anti-BCL-2 (FITC), 1 μg of anti-p53 (FITC), 1 μg of anti-phospho  
NF-κB (FITC) or anti-ubiquitin conjugated (PE) (Santa Cruz Biotechnology), for 15 min in the 
dark at room temperature. All the experiments were performed in triplicate and analyzed 
using a FACScalibur flow cytometer. The results were express as Mean Fluorescence 
Intensity (MFI) arbitrary units. This value represents the medium fluorescence intensity 
detected in the cells, which is proportional to the number of molecules labeled by the 
antibody. 
 
 2.7. Evaluation of Cell Cycle by flow cytometry 
 The cell cycle progression analysis was performed by flow cytometry, using detection 
kit PI/RNase (ImmunoStep). For that, cells were collected and washed with PBS for 5 min at 
300 xg. The pellet was resuspended in 200 µL of cold 70% ethanol, during vortex agitation, 
being incubated during 30 min on cold. After incubation time, cells were washed again and 
resuspended in 300 µL of PI/RNase solution. 
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 Cells were evaluated through CellQuestTM and data analyzed by ModfitTM. Results 
are expressed by the percentage of cells in each phase of cell cycle with a mean ± SD of at 
least three independent experiments. 
 
 2.8. Study of AKT expression levels by western blot 
 We evaluated the effect of Bortezomib, Parthenolide and Everolimus on intracellular 
signaling through the expression of AKT, in total and in the phosphorylated form by western 
blot. First, cells were incubated with 2.5 nM of BTZ, 5 µM of PTL and 5 µM of EVE for 48h. 
After this period of time, we performed cell lysates with RIPA buffer (50 mM Tris HCl at pH 
8.0, 150 mM NaCl, 1.0% NP-40, 0.5% sodium deoxycholate, 0.1% SDS and 2 mM EDTA) 
supplemented with protease and phosphatase inhibitors [Complete Mini (Roche) and 
PhosphoSTOP (Roche)] and DTT. For that, cells were centrifuged at 12 000 xg for 10 min at 
4ºC to remove the nucleus and cellular debris. The protein content of each sample was 
assessed and then the proteins were denatured. For this purpose, the protein extracts were 
boiled at 95˚C for 5 min in a denaturation buffer (Tris 0.5 mM, pH 6.8; 50% glycerol, 10% 
SDS, 10% 2β-mercaptoethanol and blue bromophenol).  For the western blotting assay, 
protein was separated by adding 30 μg of total protein to each well of a 12% SDS-PAGE gel, 
and electrophoresis was performed during 60 min at 130 V. Posteriorly proteins were 
transferred to a PVDF membrane that was incubated overnight with the primary antibody 
against p-AKT, total AKT and β-actin. This enabled the detection of the immunocomplexes 
that were later quantified using enhanced chemifluorescence detection (ECF) reagent. Total 
AKT was used as a loading control to p-AKT and β-actin was used loading control to total 
AKT. 
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3. Results 
 3.1 Bortezomib, Parthenolide and Everolimus decrease cell viability of K562 cell lines 
sensitive and resistant to Imatinib inducing apoptosis. 
 Initially we investigated if BTZ (5 nM to 100 nM), PTL (1 µM to 20 µM) and EVE (5 
µM to 50 µM), influenced the proliferation and survival of K562 and K562 RC cells. The 
exposure of K562 and K562 RC cells to BTZ, PTL and EVE induced a decrease on cell 
viability in a dose and time dependent manner, as shown in Figure 1. After 48h of exposure, 
the effect of BTZ and PTL was slightly more pronounced in K562 resistant cell line than in 
their sensitive counterpart. On the other hand, the effect of EVE was more pronounced in 
the sensitive cells than in the resistant ones. At this time, reduction of cell viability to values 
close to 50% was achieved between 25 nM and 100nM of BTZ, between 10 µM and 15 µM 
of PTL and between 15 µM and 25 µM of EVE, in K562 sensitive cell line. In K562 RC cells to 
achieve the same effect lower doses were necessary for BTZ and PTL (25-50 nM and 5-10 
µM, respectively) and in the case of EVE the doses were equal or slightly higher (15-25 µM). 
In both sensitive and resistant cells after 48h the effect is less dose-dependent and there is a 
reverse of the effect, more pronounced in the resistant cell line.  
 A non-linear regression analysis was performed to more accurately determinate IC50 
after 48h (Table 1), which confirm that K562 RC cells are more sensitive to BTZ and PTL 
and slightly less sensitive to EVE than K562 cells. 
 
Table1. Analysis of IC50 of Bortezomib, Parthenolide and Everolimus in Chronic Myeloid Leukemia 
cell lines sensitive (K562) and resistant (K562 RC) to Imatinib. 
Cell line IC50 BTZ IC50 PTL IC50 EVE 
K562 28.10 nM 12.20 µM 20.9 µM 
K562 RC 23.41 nM 5.7 µM 25.9 µM 
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Figure 1. Viabilitty dose response curves in K562 and K562 RC cell lines. Cells were incubated at a 
density of 0.5 x 106 cells/ml, during 72h, in the absence or presence of increasing concentrations of 
Bortezomib (BTZ), Parthenolide (PTL) and Everolimus (EVE), as indicated in figure. Cell viability was 
established by resazurin method, as described in Materials and Methods. Cell viability is expressed in 
percentage (%), Data are expressed as mean±SD obtained from 3 to 8 independent experiments. 
Statistic analysis was performed by comparison with control by Tukey test: * p<0.05, ** p<0.01 and 
*** p<0.001. 
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 The type of cell dead induced by the compounds was analyzed by flow cytometry 
using annexin V/propidium iodide incorporation, as shown in Figure 2, and by optical 
morphology (Figure 3). 
 We can observe that BTZ, PTL and EVE induce a decrease in the percentage of live 
cells in both K562 cell lines, and leads preferentially to an increase in the apoptotic cells that 
is especially patent in the higher doses of the compounds BTZ 10 nM, PTL 10 µM and EVE 
25 µM. In resistant cells, higher doses of PTL induce also high rates of necrosis, indicating 
that in this case dead is mediated by apoptosis and necrosis and there is activation of both 
cell death processes. Moreover, these results indicate that cell death is dose and cell type 
dependent. 
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Figure 2. Analisys of cell death induced by Bortezomib, Parthenolide and Everolimus in K562 and 
K562 RC cells by flow cytometry. K562 and K562 RC cells were incubated in a density of 0.5 x 106 
cells/ml, during 48h, in the absence and in the presence of BTZ, PTL and EVE in the concentrations 
indicated in figure. Cell death was detected by annexin v and propidium iodide staining and analyzed 
by flow cytometry. The results presented are expressed as percentage (%) of viable cells (V), early 
apoptotic cells (EA) late apoptotic/necrotic cells (LA/N) and necrosis (N), and represent the 
mean±SD obtained from three independent experiments. Statistic analysis was performed by 
comparison with control by Tukey test: * p<0.05, ** p<0.01 and *** p<0.001. 
 
 Morphologic features of K562 sensitive and resistant cell lines treated with BTZ, PTL 
and EVE confirm the results obtain by flow cytometry (Figure 3). In both cell lines, were 
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observed morphologic characteristics of apoptotic cell death, such has “blebbing”, nuclear 
fragmentation and abnormal mitosis. Characteristics of necrosis, such as cell membrane 
ruptured were also observed, especially in the resistant cells treated with PTL. The great 
majority of cells depicted also shown vacuolization that can be the result of the toxicity 
induced by the drugs or the beginning of the autophagic process (Figure 3). 
 
Figure 3. Morphological aspects of K562 and K562 RC cells treated with Bortezomib, Parthenolide 
and Everolimus. Control cells (A, B) and cells treated with BTZ (C, D), PTL (E, F) and EVE (G, H) 
were stained with Grünwald-Giemsa after 48h of incubation. Cells smears show morphologic 
features of apoptosis, such as blebbing, nuclear fragmentation, catastrophic mitosis and apoptotic 
bodies. Necrosis is also shown (black arrows). Amplification 500x. 
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 In order to know how BTZ, PTL and EVE modulate apoptotic proteins, we analyzed 
the expression levels of p53, BCL-2 and BAX. 
 As shown in Figure 4, the p53 intracellular levels decrease in K562 RC cell line 
treated with PTL and EVE, and that decrease was more accentuated at lower doses of both 
compounds (5 μM). The exposure of the sensitive cell line to PTL resulted in a decrease of 
p53 expression levels. However, these sensitive cell line show an increase of the expression 
of p53 in the presence of both concentrations of EVE and with the lower concentration of 
BTZ, but a decrease of the levels with the higher concentration of this compound was also 
observed. However, the observed differences were not significant. 
 
Figure 4. ntracellular expression levels of p53 in K562 and K562 RC cells expose to Bortezomib, 
Parthenolide and Everolimus by flow cytometry. p53 levels were analyzed by flow cytometry using 
anti-p53 (FITC). K562 cells and K562 RC cells were incubated during 48h with BTZ, PTL and EVE. 
Results are expressed as medium fluorescence intensity (MFI) and represent mean±SD of 
fluorescence intensity detected in three independent experiments. Statistic analysis was performed 
by comparison with control by Tukey test.  
 
 As represented in Figure 5A, a significant increase in intracellular BAX is observed in 
both cell lines when treated with the three compounds, separately. The increase is very 
marked in the resistant cell line when treated with BTZ or EVE. Moreover, we also 
observed a significant decrease in BCL-2 (Figure 5B) expression levels in both cell lines 
treated with BTZ, PTL and EVE, with an exception for the resistant cell line treated with 
BTZ, in which BCL-2 levels increase as well as BAX levels, however with a significant 
decrease in BCL-2/BAX ratio (Figure 5C). 
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Figure 5. Intracellular expression of BAX (A) and BCL-2 (B) and BAX/BCL-2 ratio (C) in K562 and 
K562 RC cells expose to Bortezomib, Parthenolide and Everolimus by flow cytometry. BCL-2 and 
BAX levels were analyzed by flow cytometry using monoclonal antibodies. K562 cells (pattern) and 
K562 RC cells (fill) were incubated during 48h with BTZ, PTL and EVE in the concentrations 
indicated in figure. Results are expressed as medium intensity fluorescence (MIF) and represent 
mean±SD of fluorescence intensity detected in three independent experiments. BAX/BCL-2 ratio 
was estimated as the ratio between the MIF of each molecule, in the different study conditions. 
Statistic analysis was performed by comparison with control by Tukey test: * p<0.05, ** p<0.01 and 
*** p<0.001. 
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  3.2. Cell cycle analysis 
With the intent to understand if the effects of the compounds studied are due to the 
activation of cellular check points, thereby inducing cell cycle arrest (and confirming the 
antiproliferative effect), we evaluated the distribution of cells trough the different cell phases. 
 As we can see in Table 2, in K562 sensitive cells treated with the higher dose of BTZ 
there is an increase in the percentage of cells that are arrested at G0/G1 phase, however the 
cells treated with the lower dose have no significant differences compared with control. In 
cells treated with the lower dose of PTL, cell arrest occurs at S phase. But, for the ones 
treated with the higher dose, we observe an increase in percentage of cells in G0/G1 phase. 
In the case of K562 cells sensitive to Imatinib treated with EVE, we can also observe a 
significant increase in the percentage of cells arrested at G0/G1. In K562 RC cells, exposure 
to BTZ provoked cell arrest at G2/M. On the other hand, PTL induced cell arrest at S phase 
and EVE at G0/G1 (Table 2). 
 Furthermore, in Table 2 we also can observe an increase in percentage of cells in sub 
G0/G1 peak in both cell lines treated with all drugs, confirming apoptosis previously 
described by other techniques. 
 
Table 2. Evaluation of the effect of BTZ, PTL and EVE in cell cycle in K562 and K562 RC cells. 
    Sub G0/G1 G0/G1 S G2/M 
K
5
6
2
 
Control  0,0 ± 0,0 36,7 ± 0,6 54,7 ± 2,9 8,7 ± 3,2 
BTZ 2.5 nM 1,0 ± 1,0 35,7 ± 2,1 56,3 ± 1,5 8,0 ± 3,6 
BTZ 10 nM 13,0 ± 3,6    **** 42,3 ± 2,9 46,0 ± 7,2 11,7 ± 4,5 
PRT 5 µM 8,7 ± 1,2 34,0 ± 3,5 60,0 ± 7,8 6,0 ± 4,4 
PRT 10 µM 22,0 ± 2,6    *** 44,3 ± 1,2        * 43,4 ± 1,5    12,3 ± 0,6 
EVE 5 µM 3,3 ± 2,3       ** 44,7 ± 1,5       ** 50,0 ± 3,0 5,0 ± 4,4 
EVE 25 µM 10,7 ± 0,6   **** 66,3 ± 2,5      *** 27,7 ± 3,2   **** 5,3 ± 0,6 
K
5
6
2
 R
C
 
Control  0,5 ± 0,7 44,5 ± 3,5 41,0 ± 7,1 14,5 ± 3,5 
BTZ 2.5 nM 5 ± 0,0 34,5 ± 14,8 41,5 ± 2,1 15,0 ± 0,0 
BTZ 10 nM 21,7 ± 7,6 24,0 ± 8,7 38,3 ± 3,5 37,7 ± 11,8 
PRT 5 µM 2,7 ± 0,6 37,3 ± 2,5 51,0 ± 7,8 11,7 ± 5,5 
PRT 10 µM 20,3 ± 7,6 28,5 ± 2,1 54,0 ± 0,0 17,5 ± 2,1 
EVE 5 µM 5,3 ± 1,5 56,7 ± 0,6 33,7 ± 1,2 9,7 ± 0,6 
EVE 25 µM 38,0 ± 1,4      * 65,3 ± 0,6 29,3 ± 8,1 5,3 ± 8,4 
The results presented are expressed as percentage (%) of cells present in each cycle phase, and 
represent the mean±SD obtained from three independent experiments. Statistic analysis was 
performed by comparison with control by Tukey test: * p<0.05, ** p<0.01,*** p<0.001 and **** 
p<0,0001. 
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 3.3. Evaluation of NF-κB, ubiquitin conjugates and p-AKT levels 
 The NF-κB is an important molecule in the mechanism of action of Parthenolide, 
which is a NF-κB inhibitor through IKK inhibition. NF-κB is also related with the three 
miRNAs we were studying so we also analyzed the expression levels of phosphorylated  
NF-κB (NF-kB-p) to see how BTZ, PTL and EVE affected its intracellular levels. 
 In Figure 6A, we noted that in the sensitive cell line, the higher dose of PTL and EVE 
results in an increase of NF-κB levels, opposed to a decrease observed with the both doses 
of BTZ in the same cell line. This result with PTL higher dose is a very interesting result 
considering that PTL main gold is to prevent NF-κB activation. However, in K562 RC cells 
phosphorylated NF-κB levels decrease to values around 16 MIF, when compared to control 
(22 MIF) with the administration of both doses of BTZ and PTL. With EVE the values are 
21.7 MIF to 5 µM and 19MIF to 25 µM, so it cannot be considered a significant decrease.  
 We also assed ubiquitin conjugates levels (Figure 6B), owing to the fact that one of 
the drugs under study, Bortezomib, is a proteasome inhibitor, and ubiquitin intracellular 
levels can shed light on proteasome activity. We also could obtain some results about how 
these drugs affect the ubiquitin proteasome pathway. 
 
 
Figure 6. Analysis of intracellular expression levels of NF-κB (A) and Ubiquitin (B) in K562 and K562 
RC cells upon exposure to Bortezomib, Parthenolide and Everolimus by flow cytometry. NF-κB and 
ubiquitin levels were analyzed by flow cytometry using monoclonal antibodies. K562 cells and K562 
RC cells were incubated during 48h with BTZ, PTL and EVE. Results are expressed as medium 
intensity fluorescence (MIF) and represent mean±SD of fluorescence intensity detected in three 
independent experiments. Statistic analysis was performed by comparison with control by Tukey 
test: * p<0.05, ** p<0.01 and *** p<0.001. 
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 The major difference in ubiquitin intracellular levels, as expected, was noted with the 
exposure to BTZ in both cell lines K562 and K562 RC cells. This drug increases significantly 
the level of intracellular ubiquitin conjugates, however in a dose and cell type dependent 
manner. The ubiquitin levels are higher in K562 cells treated with the lower concentration of 
BTZ and andthe inverse happens in K562 RC cells, in which the higher levels of ubiquitin are 
observed upon exposure to the highest concentration of BTZ.  
 To access the effect of BTZ, PTL and EVE in AKT pathway and explain  some of the 
mechanisms involved in the cytotoxic and cytostatic, we quantified by western blot the 
activation (A) and expression (B) of AKT in the absence and in the presence of our 
compounds. Furthermore, AKT pathway has also been shown to be related with the 
mechanism of all three miRNAs in study. The results are shown in Figure 9. 
 In the K562 cell line, the exposure to all compounds led to a decrease in p-AKT 
levels. However, in the K562 RC cell line occurred precisely the opposite (Figure 9A). AKT 
total levels were slightly elevated in all conditions, being the highest levels noted in cells 
exposed to EVE. However, these results are not statistically significant. 
 
Figure 9. p-AKT and total AKT expression levels in K562 and K562 RC cell lines.  p-AKT (A) and 
total AKT (B) levels were analyzed by western blot in K562 cells and K562 RC cells. Cell lines were 
incubated during 48h with 5nM of BTZ, 5 µM of PTL and 5 µM of EVE. After this time cells were 
lysed and prepared as described in Methods and Materials section. Results are expressed as 
percentage normalized to control and represent mean±SD of three independent experiments. 
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 3.4 MiR-21, miR-125b and miR-155 expression levels in K562 and K562 RC cell lines, 
treated with Bortezomib, Parthenolide and Everolimus. 
 The basal levels of miR-21, miR-125b and miR-155 expression are shown in Figure 7. 
We observed that there was an increase in the expression of miR-21 in K562 RC cells about 
0.46-fold more than in K562 cells. On the other hand, a significant decrease of the 
expression of miR-155 in K562 RC cells is observed when compared with K562 cells(in 
K562 cells miR-155 expression is 8.17 times higher than in K562 RC cells).In the cell line 
sensitive to Imatinib we didn´t observe no expression of miR-125b, but in the resistant cell 
line a considerable expression of miR-125b is noted (Figure 7).  
 
 
 
Figure 7. The basal expression levels of miR-21, miR-125b and miR-155 in K562 and K562 RC cells. 
We evaluated the expression of miR-21, miR-125b and miR-155 in K562 and in K562 RC cells. The 
results represent the expression levels of miRNAs normalized to nucleolar RNA, RNU6B, and are 
presented as mean ± SD of three independent experiments. Statistic analysis was performed by 
comparison with control by Tukey test: *** p<0.001. 
 
 After treatment of both cell lines with lower concentrations of BTZ (2.5 nM), PTL (5 
µM) and EVE (5 µM), expression levels were assessed, as shown in Figure 8.  
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 In K562 cell line (Figure 8A) we observed that EVE was the compound that most 
increased miR-21 and miR-155 expression. Cells exposed to BTZ present higher levels of 
miR-155 than miR-21, but the difference was not significant. The opposite happens with PTL 
exposure, where K562 present higher levels of miR-21 than miR-155. K562 cells have no 
expression of miR-125b, even upon treatment with these drugs. 
 In K562 RC cell line (Figure 8B) we could observe that BTZ and PTL promoted the 
higher expression levels of miR-155. The low expression of miR-21 and miR-155 upon 
exposure to EVE is in clear contrast with what happen in K562 cells. While in K562 EVE 
induces an increase in miR-21 and miR-155 expression levels 2 times higher than the control, 
in K562 RC cells EVE induces a slightly decrease, specially noted in miR-155 which decreases 
to 0,7 in relation to control (1). BTZ and PTL exposure promoted only an increase of miR-
155 expression in K562 RC cells, 1.26 and 1.36, respectively, in relation to control (1) . 
Although miR-125b expression increased in K562 RC cells in relation to K562 cells, the 
exposure to the different compounds induce no significant different in the expression levels 
of this miRNA. 
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Figure 8. The expression levels of miR-21, miR-125b and miR-155 in K562 and K562 RC cell lines 
treated with Bortezomib (BTZ), Parthenolide (PTL) and Everolimus (EVE). We evaluated the 
expression of miR-21, miR-125b and miR-155 in K562 (A) and in K562 RC cells (B), cultured in the 
absence and presence of BTZ, PTL and EVE, during 48h. The increase or decreased of miRNAs levels 
is normalized to untreated cells (miRNA expression levels of untreated cells are represented by the 
green line). The results represent mean±SD of three independent experiments. Statistic analysis was 
performed by comparison with control by t- test: * p<0.05 and ** p<0.01. 
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4. Discussion 
 This study was initiated by the evaluation of cytotoxic effect of Bortezomib, 
Parthenolide and Everolimus in two CML cell lines, one sensitive to Imatinib and other 
resistant to this tyrosine kinase inhibitor (TKI). Analyzing the cytotoxicity curves and the 
IC50 values of the three compounds, the cytotoxic effect of Bortezomib and Parthenolide 
seems to be more effective in K562 RC pointing out that these compounds can be used in 
patients that have developed a resistance to Imatinib therapy. In contrast, Everolimus was 
more effective in K562 cells, suggesting that this compound would have better effects in 
patients who have no previous resistance to Imatinib, than the ones that already present a 
resistance to TKI.  
 Bortezomib is a potent and selective proteasome inhibitor, and in our work we can 
see that the effect it exerts in the CML cell lines it’s through ubiquitin-proteasome pathway, 
as ubiquitin levels are elevated in K562 and K562 RC cell lines incubated with Bortezomib, 
during 48h. With proteasome inhibition promoted by Bortezomib, ubiquitinated proteins are 
all disperse in the intracellular space, making possible to quantify the ubiquitin levels. 
 Moreover, NF-κB,  a transcription factor that has crucial roles in inflammation, 
immunity, cell proliferation and apoptosis (Viatour P et al., 2005), has been implicated in the 
mechanism responsible for the antitumor effect of proteasomes inhibitors (Melo and Chuah, 
2008). Bortezomib, inhibits proteasome degradation of IκB, the inhibitor of NF-kB, and 
thereby it binds to NF-κB inhibiting its activation. Activation of NF-kB mainly occurs via IkB 
kinase (IKK)-mediated phosphorylation of inhibitory molecules, including IkB-The 
inhibition NF-κB activation, in turn, inhibits the transcription of antiapoptotic and antioxidant 
genes. Moreover, NF-κB has also been related with the promotion of chemoresistance 
(Ludwig et al., 2005) and our results also show that the basal levels of NF-κB in the Imatinib 
resistant cell line are higher than in the sensitive line. Therefore, we quantified the activated 
NF-κB in both cell lines treated with Bortezomib and observed that there is a decrease in 
the sensitive cell line and in the resistant one. Furthermore, Bortezomib was more potent in 
inhibiting viability in K562 RC cells than K562 cells, what indicates a direct correlation with 
decrease in NF-κB activity. For that reason, Bortezomib presents itself as a possible 
alternative to use in CML patients with resistance to Imatinib. 
 The tumor suppressor protein p53 is another important substrate for proteasomal 
degradation. p53 levels and activity are controlled in large part through regulated 
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ubiquitination and subsequent destruction by proteasome. Inhibition of proteasome leads to 
p53 stabilization. This protein promotes the induction of the proapoptotic protein BAX that 
is also a proteasomal substrate. BAX, in turn, inhibits the antiapoptotic protein BCL-2. All 
this is related with the induction of apoptosis (Ludwig et al., 2005). Our results suggest that 
in both cell lines there is stabilization in p53, as the levels of the molecule is similar in treated 
cells and in control. As expected we can observe a significant decrease in BCL-2 and an 
increase in BAX levels, in the K562 cells both sensitive and resistant to Imatinib when 
treated with Bortezomib. 
 Bortezomib has shown the ability to arrest the cells in G2/M phase (Melo and Chuah, 
2008), in Bcr/Abl-positive cell lines sensitive or resistant to Imatib, in concentrations similar 
to ours (Gatto et al., 2003) and in a P-glycoprotein (P-gp) positive leukemia line K562/A02 
with 100nM of Bortezomib (LÜ et al., 2010). However our results differ from this.  
 We could observe that in cells treated with the lower dose of Bortezomib, 5 nM, 
there is no visible cell cycle arrest. This result might be dependent of the lower dose, which 
did not have capacity to induce cell arrest. But, in cells treated with the high concentration 
of Bortezomib, 10 nM, cell cycle arrest occurs at G0/G1. Our results, albeit different from 
other authors, are in concordance with the study conducted by Albero and colleagues 
(Albero et al., 2010) that show that in Imatinib sensitive and resistant BCR-ABL1-expressing 
cells Bortezomib induces cell arrest at G0/G1. These authors explain the results with the 
observed reduction of Rb phosphorylation and, consequently increase in the activity of Rb, a 
tumor suppressor protein that regulates transition from G1 into S phase. The cells used in 
our study are BCR-ABL expressing cells, which allows us to relate our results with these 
previously described. It is possible that the same mechanism is occurring in our case, and 
further studies will be necessary to analyze Rb to prove this relation. 
 Parthenolide is a known NF-κB inhibitor that acts by directly binding to IκK, thus 
preventing its release from NF-κB subunits and consequent activation of NF-κB. Lack of  
NF-κB activity render cancer cells prone to undergo apoptosis and become sensitized to 
cancer drug induced cell death (Guzman et al., 2005). Parthenolide has also show to inhibit 
STATs mediated apoptotic gene transcription and increase intracellular reactive oxygen 
species (ROS). The apoptotic mechanism induced by generation of ROS results in a 
proapoptotic BAX conformational change, release of cytochrome c from mitochondria and 
caspase activation. Parthenolide also amplifies the apoptotic signal through the sensitization 
of cancer cells to extrinsic apoptosis, induced by TNF-α (Pajak et al., 2008).  
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 In the studies conducted, our results indicate that in the K562 resistant cells NF-κB 
decreases, allowing us to presume that in this cell line Parthenolide works through NF-κB 
pathway, as described in literature. However, in K562 cells sensitive to Imatinib we can 
observe just a slight decrease of NF-κB in the cells treated with 5 nM of Parthenolide. On 
the other hand, a significant increase of NF-κB in cells treated with 10 nM of Parthenolide 
was observed. This last result is quite discrepant from what is found in literature. Guzman 
and colleagues verified that Parthenolide-mediated apoptosis is strongly associated with 
inhibition of NF-κB (Guzman et al., 2005). 
 Observing the dose response curve and cell death type in both cell lines treated with 
Parthenolide, we can remark that the antiproliferative and cytotoxic effect is dose, time and 
cell type dependent. In K562 cells, treated with Parthenolide 10 nM during 48h we observe a 
significant decrease in cell viability about 34.6% higher than the observed in cells incubated 
with 5 nM of this drug. These results, along with the results obtained by flow cytometry, 
showing that a large proportion of cells treated with 10 nM of Parthenolide present a high 
amount of necrosis, allow us to assume that this dose activate different cell death pathways. 
 These pathways can influence the increase in NF-κB, since it has protective 
characteristics in the cell, regulating the expression of genes that keep the cell proliferating 
and protects the cell from conditions that would otherwise cause apoptosis. It is also 
activated in response to stimuli such as cytokines, LPS and DNA damage. It is known that 
Parthenolide can act through other pathways besides the NF-κB, such as ROS production. 
ROS and NF-κB signaling pathways interact in many ways. NF-κB is related to the 
transcription of genes that influence ROS levels in the cell and in turn ROS levels also 
regulate the levels of NF-κB activity. Depending on the context, ROS can both activate and 
inhibit NF-κB signaling (Morgan and Liu, 2011). Having this in mind, we can speculate that 
with the higher dose, Parthenolide induces high production of ROS, leading to an increase of 
NF-κB in an attempt to protect the cell from the harms of the drug related with oxidative 
stress. If the increase in NF-κB is higher than the capacity of Parthnolide to inhibits this 
transcription factor, these observations could explain our results.  
Besides this, Parthenolide was been shown in melanoma cells to have an activity 
dependent on cell context (Czyz et al., 2010). This is another reason that could explain our 
results. Another explanation could be that, because there is a great amount of death induced 
by the higher dose of Parthenolide, only a few viable cells are detected by flow cytometry 
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and this few viable cells are responsible for the increased NF-κB levels observed. These 
viable cells, not being affected by Parthenolide in its principal target, the NF-κB pathway, 
were in some ways stressed enough to start producing NF-κB in a protective way, being 
responsible for the increase that we detected. 
 Another interesting fact is that in AML cells, genetic studies using a dominant negative 
repressor of NF-κB activity have shown that inhibition of NF-κB alone is not sufficient to 
mediate the robust cell death observed with Parthenolide (Guzman et al., 2005), meaning 
that other pathways are activated simultaneously. Parthenolide has been shown to suppress 
STAT3 activity (Pajak et al., 2008). K562 cell line has constitutive activation of STAT3 and a 
previous study presented that STAT3 plays a critical role in the survival of K562 cells, 
because knockdown of STAT3 by STAT3 siRNA caused a decrease in STAT3 protein level, 
inhibition of growth and proliferation, cell cycle arrest, visible morphologic changes, and 
induction of apoptosis in K562 cells (Ma et al., 2010). STAT3 inhibition could represent a 
viable strategy to CML therapy, meaning that Parthenolide could be a viable therapeutic 
option.  
 The molecular mechanism of Parthenolide mediated apoptosis is also strongly 
associated with proapoptotic activation of p53. In our studies we could not find a significant 
difference in p53 expression levels, in both K562 and K562 RC cell lines. Nonetheless, it had 
been shown that Parthenolide induced cell death in Chronic Lymphocytic Leukemia (CLL) 
cells in a p53 independent way, being p53 upregulation not so important to Parthenolide 
induced apoptosis in this cancer cells (Steele et al., 2006). 
 Our results show that the increase in BCL-2 expression levels in K562 and K562 RC 
cells, along with the diminished levels of BAX, can point to the involvement of the 
mitochondrial pathway and activation of ROS as the principal mechanism of action of 
Parthenolide in these cells. Our results also show that ubiquitin levels are slightly elevated in 
K562 cells treated with 10 nM of Parthenolide, despite this not being statistically significant. 
If NF-κB levels are increased this means that IκB is ubiquitinated and therefore not bind to 
NF-κB subunits, what is in accordance with our results. 
 In the vast majority of patients with chronic myeloid leukemia that have developed 
resistance to Imatinib, the resistance is the result of a point mutation in BCR-ABL gene. 
Activation of the tyrosine kinase fusion product BCR-ABL is absolutely required for the 
development of this type of leukemia, and molecularly defines this disease.  
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 As BCR-ABL fusion gene has been shown to activate the PI3K/AKT/mTOR pathway, 
mTOR inhibitors might have a significant therapeutic effect in leukemias that have acquired 
BCR-ABL mutations (Easton and Houghton, 2006). 
 Everolimus is a derivate of rapamycin and an mTOR inhibitor. mTOR is a serine-
threonine kinase downstream of PI-3 kinase (PI3K) that is activated upon phosphorylation by 
AKT (Melo and Chuah, 2008). The late re-activation of mTOR in response to Imatinib 
(Mancini, M. et al., 2010) is possibly responsible for the development of an Imatinib resistant 
phenotype (Melo and Chuah, 2008). Everolimus revokes mTOR late re-activation, making 
this drug very promising in the therapy of CML resistant to Imatinib. 
 Our results show that Everolimus induces in K562 cells, sensitive and resistant to 
Imatinib, a cytotoxic effect. Direct inhibitors of mTOR and those pathways activating mTOR, 
subsequently induce autophagy, being this protein implicated in the inhibition of autophagy 
(Mancini, M. et al., 2010). Everolimus has shown in our studies to provable induce autophagy, 
as we can see by the cytoplasmic vacuoles present in the cell smears. Additional studies will 
be necessary to prove that the cytoplasmatic vacuoles are in fact a result of autophagy. Such 
studies can comprise the assessment of beclin, LSII and/or LDIII levels by western blot. 
 Everolimus showed that in both K562 cell lines, besides the cytotoxic effect, 
observed by the apoptosis triggering, it also has a cytostatic effect on the cells that is 
confirmed by the cell cycle arrest at G0/G1. The inhibitory effect of rapamycin on the in 
vitro growth of primary CML cells is directly related to induction of G1 cell cycle arrest and 
subsequent apoptosis (Melo and Chuah, 2008), what is in concordance with our results. 
 Everolimus interferes with the assembly of both mTOR complexes: mTORC1 and 
mTORC2. The inhibition of mTORC2 results in the de-phosphorylation of AKT at Ser473 in 
the hydrophobic motif of C-terminal tail which is required for AKT full activation and 
prevents AKT re-phosphorylation in response to Imatinib (Mancini, M. et al., 2010, Zeng et 
al., 2007). We evaluated the levels of phosphorylated AKT in K562 and K562 RC cells 
treated with Everolimus. K562 cell line sensitive to Imatinib had a decrease in p-AKT, what is 
in concordance with the mechanism of action of Everolimus. However, K562 cells resistant 
to Imatinib had an increase in p-AKT, but this effect is not significant. 
 Various studies have shown that combination of Imatinib and Everolimus acts 
synergistically in BCR-ABL positive cell lines (Alves, 2011, Mancini, Manuela et al., 2010, 
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Mohi et al., 2004, Zeng et al., 2007), although this effect is more pronounced in cells with 
moderate resistance to Imatinib (Dengler et al., 2005). 
 Additionally, we must have in mind that BCR-ABL kinase mutations are very common 
in patients with resistance to Imatinib therapy. Previous studies showed that the presence of 
oncogenic KRAS mutations was associated with lack of benefit after Everolimus therapy (Di 
Nicolantonio et al., 2010), and also to Imatinib resistance in some CML patients (Agarwal et 
al., 2008). These alterations in Imatinib resistant cells might have significant influence in the 
pathways through which Everolimus works, diminishing the cytotoxic effect of Everolimus in 
K562 resistant cell line. 
In this study we observed that miR-21 has higher expression levels in K562 RC cells 
than in K562 cells, suggesting a possible role of this miRNA in Imatinib resistance. As 
previously referred, miR-21 up-regulation induces resistance to Daunorubicin in the K562 
cell line by regulating the expression of PTEN. Haitao Bai (Bai et al., 2011) demonstrated 
that miR-21 overexpression down-regulates PTEN activity and thereby increases the activity 
of AKT. There are other studies that also show that miR-21 overexpression contributes to 
resistance to therapy in breast cancer (Gong et al., 2011), ovarian cancer (Echevarría-Vargas 
et al., 2014) and other neoplasias (Pan et al., 2010). In K562 cells exposed to Bortezomib, 
Parthenolide and Everolimus there is an increase in miR-21 expression. The total AKT levels 
are elevated in K562 cells in all conditions; however the p-AKT levels are decreased. This 
could be explained based on the mechanism of action of the drugs, and not by the action of 
the miRNAs. Everolimus could be an example of this, as it acts trough the dephosphorylation 
of AKT, what explains the low levels of p-AKT in cells treated with this drug. The increase in 
p-AKT, caused by miR-21 overexpression, is probably outweighed with the action of 
Everolimus. MiR-21 overexpression after treatment with rapamycin, from which Everolimus 
is a derivative, has been previously shown in endothelial cells (Jin et al., 2013) and the same 
study also showed that inhibition of miR-21 abrogated rapamycin mediated inhibition of 
endothelial proliferation. The increase in miR-21 expression induced by rapamycin was likely 
a result in the inhibition of Raptor, a specific component of mTORC1, relating mTORC 
components with the regulation of the miRNAs expression levels. However, further 
mechanism of miR-21 mTORC1 regulation should be discussed in later studies.  
Knockdown of miR-21 has been presented has a novel therapy in leukemia cells (Feng 
et al., 2010). Downregulation of miR-21 has shown to enhance chemotherapeutic effect of 
taxol in breast carcinoma cells (Mei et al., 2010). Our results also show a decrease in mir-21 
Discussion 
- 61 - 
 
expression levels in K562 RC cells when exposed to Bortezomib, Parthenolide and 
Everolimus what can indicate that these compounds have a role in the decrease of miR-21 in 
K562 RC cells and can be used in patients with resistance to Imatinib therapy, because 
render the cells more sensitive to chemotherapy.  
A study (Talotta et al., 2009) showed that in response to RAS signaling, AP-1 induces 
miR-21 expression. RAS is the initiating molecule of the RAS/MAPK cascade, one of the 
known subtracts of BCR-ABL fusion gene, leading to decontrolled proliferation of leukemic 
cells (Alves, 2011). Everolimus has been shown to interfere with the generation of AP-1 
(Daniel et al., 2010). Being so, the inhibition of AP-1 by Everolimus could be the reason why 
miR-21 expression levels are decreased in K562 RC cells treated with this compound.  
Another study (Dan et al., 2008) showed that in PTEN-null/inactive prostate cancer 
cells, mTOR, downstream from AKT, by interaction with and stimulation of IκK, controls 
NF-κB activity. It seems that the mTOR-associated protein Raptor is required for the ability 
of AKT to induce NF-κB activity. In the study, rapamycin, an analogue of Everolimus, 
suppressed the IκK activity in PTEN-deficient prostate cancer cells through a mechanism that 
may involve dissociation of Raptor from mTOR. We can hypothesize that the same happens 
in our cells. Our cells express miR-21 that at least inactivates PTEN. In that case, Everolimus 
exposure would block mTOR and diminish AKT ability to induce NF-κB. On the other hand, 
NF-κB has been shown to induce miR-21 expression (O'Connell et al., 2011), so the lack of 
this molecule would probable decrease miR-21 levels. Furthermore, as both Bortezomib and 
Parthenolide are known for its capacity to inhibit NF-κB, miR-21 could also be decrease by 
this mechanism in the cells treated with these compounds. 
 Overexpression of miR-125b has been proposed to contribute to tumor resistance 
to chemotherapy. MiR-125b has been showed to induce resistance in K562, THP-1 and 
Jurkat cells to the drug Daunorubicin by reducing apoptosis, while the suppression of miR-
125b was found to enhance Daunorubicin cytotoxicity in REH cells (Zhou et al., 2014). 
 In our studies we did not detect any expression levels of miR-125b in K562 cells but 
there was a significant expression of miR-125b in K562 RC cells, what is in accordance with 
the foregoing. The lack of expression of mir-125b in K562 cells, and its expression in 
resistant ones may mean that this miRNA might have a role in Imatinib resistance. When 
both cell lines were incubated with Bortezomib, Parthenolide and Everolimus no expression 
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of miR-125 was observed in the K562 cells, however all compounds contributed to a 
tenuous decreased of the levels of miR-125b in K562 RC cells.  
 In K562 cells incubated with Bortezomib, Parthenolide and Everolimus, we noticed an 
increase in miR-155 expression levels, being the highest increase in cells treated with 
Everolimus. Nevertheless, in K562 RC cells miR-155 levels increased after incubation with 
Bortezomib and Parthenolide, but decreased with Everolimus incubation.  
 Transcription of miR-155 is up-regulated by AP-1 (O'Connell et al., 2011) and as 
previously stated, Everolimus had been shown to interfere with the generation of AP-1. This 
influence of Everolimus in AP-1 action can lead to the decrease of miR-155 observed in cells 
resistant to Imatinib. Being miR-155 an oncomir, the decrease in miR-155 expression levels 
induced by Everolimus can indicates that Everolimus might be a good therapy to use in CML 
patients with resistance to Imatinib and miR-155 increased levels. 
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5. Conclusion 
 In summary, our results reveal that the compounds use in this study, Bortezomib, 
Parthenolide and Everolimus, are able to induce a cytotoxic effect in both K562 cells 
sensitive to Imatinib and in K562 cells resistant to this tyrosine kinase inhibitor. In fact 
Bortezomib and Parthenolide revealed to be more effective in the K562 resistant cells than 
in the sensitive ones. These results may indicate that these two compounds could be used as 
an alternative therapy in CML patients with resistance to Imatinib. 
 Furthemore, our results also point to an involvement of miR-21, miR-125b and miR-
155 in the acquisition of resistance to Imatinib. The exposure to Bortezomib, Parthenolide 
and Everolimus was able to modulate the expression levels of these miRNAs suggesting that 
they may provide interesting drug targets for the sensitization of tumor cells to 
chemotherapy and could be applied to treat chemotherapy resistance in leukaemia patients. 
 However, these results must be validated using leukemic cells obtained from CML 
patients with and without resistance to Imatinib. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
 
 
 
 
 
 
 
REFERENCES 
 
 
 
Reference 
- 65 - 
 
 
  
References 
- 66 - 
 
AGARWAL, A., [et al.] - An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia. 
Leukemia. Vol. 22. n.º 12 (2008). pp. 2269-2272.  
 
ALBERO, M. P., [et al.] - Bortezomib decreases Rb phosphorylation and induces caspase-dependent 
apoptosis in Imatinib-sensitive and -resistant Bcr-Abl1-expressing cells. Oncogene. Vol. 29. 
n.º 22 (2010). pp. 3276-3286.  
 
ALVES, Raquel - Avaliação molecular dos mecanismos envolvidos na sensibilidade e resistência ao 
Imatinib independente do BCR-ABL em Leucemia Mielóide Crónica. University of Coimbra, 
2011. Masters Thesis 
 
ANDROULIDAKI, A., [et al.] - The kinase Akt1 controls macrophage response to lipopolysaccharide 
by regulating microRNAs. Immunity. Vol. 31. n.º 2 (2009). pp. 220-31.  
 
ARMAND, Philippe - Novel Therapies for Acute Lymphoblastic Leukemia. Molecular Oncology. Vol. 
1. n.º 2 (2007).  
 
BAI, Haitao, [et al.] - Involvement of miR-21 in resistance to daunorubicin by regulating PTEN 
expression in the leukaemia K562 cell line. FEBS Letters. Vol. 585. n.º 2 (2011). pp. 402-408.  
 
BALLESTAR, E.; ESTELLER, M. - Methyl-CpG-binding proteins in cancer: blaming the DNA 
methylation messenger. Biochem Cell Biol. Vol. 83. n.º 3 (2005). pp. 374-84.  
 
BOUSQUET, M., [et al.] - MicroRNA miR-125b causes leukemia. Proc Natl Acad Sci U S A. Vol. 107. 
n.º 50 (2010). pp. 21558-63.  
 
BREVING, Kimberly; ESQUELA-KERSCHER, Aurora - The complexities of microRNA regulation: 
mirandering around the rules. Int J Biochem Cell Biol. Vol. 42. n.º 8 (2010). pp. 1316-1329.  
 
BUSCAGLIA, L. E.; LI, Y. - Apoptosis and the target genes of microRNA-21. Chin J Cancer. Vol. 30. 
n.º 6 (2011). pp. 371-80.  
 
CALIN, G. A., [et al.] - Frequent deletions and down-regulation of micro- RNA genes miR15 and 
miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. Vol. 99. n.º 24 
(2002). pp. 15524-9.  
 
CALIN, G. A., [et al.] - Human microRNA genes are frequently located at fragile sites and genomic 
regions involved in cancers. Proc Natl Acad Sci U S A. Vol. 101. n.º 9 (2004). pp. 2999-3004.  
 
CHEN, L., [et al.] - miR-155 mediates drug resistance in osteosarcoma cells via inducing autophagy. 
Exp Ther Med. Vol. 8. n.º 2 (2014). pp. 527-532.  
 
CHOTINANTAKUL, Kamonnaree; LEEANANSAKSIRI, Wilairat - Hematopoietic Stem Cell 
Development, Niches, and Signaling Pathways. Bone Marrow Research. Vol. 2012. (2012). p. 
16.  
 
CHOUDHURY, S. N.; LI, Y. - miR-21 and let-7 in the Ras and NF-kappaB Pathways. Microrna. Vol. 1. 
n.º 1 (2012). pp. 65-9.  
 
CORTES, J. E., [et al.] - Investigational strategies in chronic myelogenous leukemia. Hematol Oncol 
Clin North Am. Vol. 18. n.º 3 (2004). pp. 619-39, ix.  
 
CZYZ, M., [et al.] - Cell context-dependent activities of parthenolide in primary and metastatic 
melanoma cells. Br J Pharmacol. Vol. 160. n.º 5 (2010). pp. 1144-57.  
 
Reference 
- 67 - 
 
DAN, H. C., [et al.] - Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in 
association with IKK. Genes Dev. Vol. 22. n.º 11 (2008). pp. 1490-500.  
 
DANIEL, Carolin[et al.] - Enhancement of antigen-specific Treg vaccination in vivo. Proceedings of 
the National Academy of Sciences. Vol. 107. n.º 37 (2010). pp. 16246-16251.  
 
DENGLER, J., [et al.] - Combination of imatinib with rapamycin or RAD001 acts synergistically only 
in Bcr-Abl-positive cells with moderate resistance to imatinib. Leukemia. Vol. 19. n.º 10 
(2005). pp. 1835-8.  
 
DI NICOLANTONIO, F., [et al.] - Deregulation of the PI3K and KRAS signaling pathways in human 
cancer cells determines their response to everolimus. J Clin Invest. Vol. 120. n.º 8 (2010). pp. 
2858-66.  
 
DICK, Jean C. Y. Wang; John E. - Cancer Stem Cells. In DeVita, Hellman, and Rosenberg's Cancer: 
Principles & Practice of Oncology. Wolters Kluwer/Lippincott Williams & Wilkins, 2008.Cap. 
10. 9780781772075 
 
EASTON, J. B.; HOUGHTON, P. J. - mTOR and cancer therapy. Oncogene. Vol. 25. n.º 48 (2006). 
pp. 6436-46.  
 
ECHEVARRÍA-VARGAS, Ileabett M.; VALIYEVA, Fatma; VIVAS-MEJÍA, Pablo E. - Upregulation of 
miR-21 in Cisplatin Resistant Ovarian Cancer via JNK-1/c-Jun Pathway. PLoS One. Vol. 9. n.º 
5 (2014). p. e97094.  
 
ESTELLER, M. - Epigenetics in cancer. N Engl J Med. Vol. 358. n.º 11 (2008). pp. 1148-59.  
 
FENG, Yimei; CHEN, Xinghua; GAO, Lei - Knockdown of miR-21 as a Novel Approach for Leukemia 
Therapy. Journal of the Formosan Medical Association. Vol. 109. n.º 9 (2010). pp. 621-623.  
 
FIRATLIGIL, B.; BIRAY AVCI, C.; BARAN, Y. - miR-17 in imatinib resistance and response to 
tyrosine kinase inhibitors in chronic myeloid leukemia cells. J BUON. Vol. 18. n.º 2 (2013). 
pp. 437-41.  
 
FRAZER, R.; IRVINE, A. E.; MCMULLIN, M. F. - Chronic Myeloid Leukaemia in The 21st Century. 
Ulster Med J. Vol. 76. n.º 1 (2007). pp. 8-17.  
 
FRIEDMAN, J. M., [et al.] - The putative tumor suppressor microRNA-101 modulates the cancer 
epigenome by repressing the polycomb group protein EZH2. Cancer Res. Vol. 69. n.º 6 
(2009). pp. 2623-9.  
 
GATTO, S, [et al.] - The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in 
Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate. 2003.  
 
GONCALVES, A. C., [et al.] - Oxidative stress mediates apoptotic effects of ascorbate and 
dehydroascorbate in human Myelodysplasia cells in vitro. Toxicol In Vitro. Vol. 27. n.º 5 
(2013). pp. 1542-9.  
 
GONG, C., [et al.] - Up-regulation of miR-21 Mediates Resistance to Trastuzumab Therapy for 
Breast Cancer. Journal of Biological Chemistry. Vol. 286. n.º 21 (2011). pp. 19127-19137.  
 
GUIL, S.; ESTELLER, M. - DNA methylomes, histone codes and miRNAs: tying it all together. Int J 
Biochem Cell Biol. Vol. 41. n.º 1 (2009). pp. 87-95.  
 
GUZMAN, M. L., [et al.] - The sesquiterpene lactone parthenolide induces apoptosis of human acute 
myelogenous leukemia stem and progenitor cells. Blood. Vol. 105. n.º 11 (2005). pp. 4163-9.  
 
References 
- 68 - 
 
HANAHAN, D.; WEINBERG, R. A. - The hallmarks of cancer. Cell. Vol. 100. n.º 1 (2000). pp. 57-70.  
 
HATZIAPOSTOLOU, M.; ILIOPOULOS, D. - Epigenetic aberrations during oncogenesis. Cell Mol 
Life Sci. Vol. 68. n.º 10 (2011). pp. 1681-702.  
 
HAYFLICK, L. - Living forever and dying in the attempt. Exp Gerontol. Vol. 38. n.º 11-12 (2003). pp. 
1231-41.  
 
HEHLMANN, Rüdiger; HOCHHAUS, Andreas; BACCARANI, Michele - Chronic myeloid leukaemia. 
The Lancet. Vol. 370. n.º 9584 (2007). pp. 342-350.  
 
HOFFMAN, C. M.; CALVI, L. M. - Minireview: Complexity of Hematopoietic Stem Cell Regulation in 
the Bone Marrow Microenvironment. Mol Endocrinol. (2014). p. me20141079.  
 
IORIO, M. V.; CROCE, C. M. - MicroRNA dysregulation in cancer: diagnostics, monitoring and 
therapeutics. A comprehensive review. EMBO Mol Med. Vol. 4. n.º 3 (2012). pp. 143-59.  
 
IORIO, M. V.; PIOVAN, C.; CROCE, C. M. - Interplay between microRNAs and the epigenetic 
machinery: an intricate network. Biochim Biophys Acta. Vol. 1799. n.º 10-12 (2010). pp. 694-
701.  
 
JIN, Chongying, [et al.] - MicroRNA-21 mediates the rapamycin-induced suppression of endothelial 
proliferation and migration. FEBS Letters. Vol. 587. n.º 4 (2013). pp. 378-385.  
 
JORDAN, C. T.; GUZMAN, M. L.; NOBLE, M. - Cancer stem cells. N Engl J Med. Vol. 355. n.º 12 
(2006). pp. 1253-61.  
 
KONG, F., [et al.] - miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-
apoptotic Bcl-2 antagonist killer 1. J Huazhong Univ Sci Technolog Med Sci. Vol. 31. n.º 4 
(2011). pp. 543-9.  
 
KRISTENSEN, L. S.; NIELSEN, H. M.; HANSEN, L. L. - Epigenetics and cancer treatment. Eur J 
Pharmacol. Vol. 625. n.º 1-3 (2009). pp. 131-42.  
 
LE, M. T.[et al.] - MicroRNA-125b is a novel negative regulator of p53. Genes Dev. Vol. 23. n.º 7 
(2009). pp. 862-76.  
 
LEE, D. W., [et al.] - Loss of SHIP-1 protein expression in high-risk myelodysplastic syndromes is 
associated with miR-210 and miR-155. Oncogene. Vol. 31. n.º 37 (2012). pp. 4085-94.  
LEE, R. C.; FEINBAUM, R. L.; AMBROS, V. - The C. elegans heterochronic gene lin-4 encodes small 
RNAs with antisense complementarity to lin-14. Cell. Vol. 75. n.º 5 (1993). pp. 843-54.  
 
LI, Y., [et al.] - Inhibition of BCR/ABL protein expression by miR-203 sensitizes for imatinib mesylate. 
PLoS One. Vol. 8. n.º 4 (2013). p. e61858.  
 
LIU, X., [et al.] - Regulation of microRNAs by epigenetics and their interplay involved in cancer. J Exp 
Clin Cancer Res. Vol. 32. (2013). p. 96.  
 
LO CELSO, C.; SCADDEN, D. T. - The haematopoietic stem cell niche at a glance. J Cell Sci. Vol. 
124. n.º Pt 21 (2011). pp. 3529-35.  
 
LOBO, N. A., [et al.] - The biology of cancer stem cells. Annu Rev Cell Dev Biol. Vol. 23. (2007). pp. 
675-99.  
 
LÜ, S., [et al.] - The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line 
K562/A02. International Journal of Laboratory Hematology. Vol. 32. n.º 1p1 (2010). pp. e123-
e131.  
Reference 
- 69 - 
 
 
LUDWIG, Heinz, [et al.] - Proteasome inhibition and its clinical prospects in the treatment of 
hematologic and solid malignancies. Cancer. Vol. 104. n.º 9 (2005). pp. 1794-1807.  
 
MA, L. D., [et al.] - Effects of STAT3 silencing on fate of chronic myelogenous leukemia K562 cells. 
Leuk Lymphoma. Vol. 51. n.º 7 (2010). pp. 1326-36.  
 
MANCINI, M., [et al.] - RAD 001 (everolimus) prevents mTOR and Akt late re-activation in 
response to imatinib in chronic myeloid leukemia. J Cell Biochem. Vol. 109. n.º 2 (2010). pp. 
320-8.  
 
MANCINI, Manuela, [et al.] - mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib 
in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein. Leukemia 
Research. Vol. 34. n.º 5 (2010). pp. 641-648.  
 
MEI, M., [et al.] - Downregulation of miR-21 enhances chemotherapeutic effect of taxol in breast 
carcinoma cells. Technol Cancer Res Treat. Vol. 9. n.º 1 (2010). pp. 77-86.  
 
MELO, J. V.; CHUAH, C. - Novel agents in CML therapy: tyrosine kinase inhibitors and beyond. 
Hematology Am Soc Hematol Educ Program. (2008). pp. 427-35.  
 
MOHI, M. G., [et al.] - Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for 
the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci U S A. Vol. 101. 
n.º 9 (2004). pp. 3130-5.  
 
MOISON C, Guieysse-Peugeot AL, Arimondo PB - DNA methylation in cancer 2013. Disponível em 
WWW: <http://AtlasGeneticsOncology.org/Deep/DNAMethylationID20127.html>.  
 
MORGAN, M. J.; LIU, Z. G. - Crosstalk of reactive oxygen species and NF-kappaB signaling. Cell Res. 
Vol. 21. n.º 1 (2011). pp. 103-15.  
 
O'BRIEN, C. A.; KRESO, A.; JAMIESON, C. H. - Cancer stem cells and self-renewal. Clin Cancer Res. 
Vol. 16. n.º 12 (2010). pp. 3113-20.  
 
O'CONNELL, R. M.; ZHAO, J. L.; RAO, D. S. - MicroRNA function in myeloid biology. Blood. Vol. 
118. n.º 11 (2011). pp. 2960-9.  
 
ORKIN, S. H.; ZON, L. I. - Hematopoiesis: an evolving paradigm for stem cell biology. Cell. Vol. 132. 
n.º 4 (2008). pp. 631-44.  
 
PAJAK, B.; GAJKOWSKA, B.; ORZECHOWSKI, A. - Molecular basis of parthenolide-dependent 
proapoptotic activity in cancer cells. Folia Histochem Cytobiol. Vol. 46. n.º 2 (2008). pp. 129-
35.  
 
PAN, Xuan; WANG, Zhao-Xia; WANG, Rui - MicroRNA-21: A novel therapeutic target in human 
cancer. Cancer Biology & Therapy. Vol. 10. n.º 12 (2010). pp. 1224-1232. 
  
PAVET, V., [et al.] - Towards novel paradigms for cancer therapy. Oncogene. Vol. 30. n.º 1 (2011). 
pp. 1-20.  
 
PIRIYAPONGSA, J.; MARINO-RAMIREZ, L.; JORDAN, I. K. - Origin and evolution of human 
microRNAs from transposable elements. Genetics. Vol. 176. n.º 2 (2007). pp. 1323-37.  
 
PORTELA, A.; ESTELLER, M. - Epigenetic modifications and human disease. Nat Biotechnol. Vol. 28. 
n.º 10 (2010). pp. 1057-68.  
 
References 
- 70 - 
 
REINHART, B. J., [et al.] - The 21-nucleotide let-7 RNA regulates developmental timing in 
Caenorhabditis elegans. Nature. Vol. 403. n.º 6772 (2000). pp. 901-6.  
 
RODRIGUEZ-PAREDES, M.; ESTELLER, M. - Cancer epigenetics reaches mainstream oncology. Nat 
Med. Vol. 17. n.º 3 (2011). pp. 330-9.  
 
ROUHI, A., [et al.] - MiRNAs, epigenetics, and cancer. Mamm Genome. Vol. 19. n.º 7-8 (2008). pp. 
517-25.  
 
SARMENTO-RIBEIRO, A., [et al.] - Bortezomib - A Potential Therapeutic Approach in B Chronic 
Lymphocytic Leukaemia. ASH Annual Meeting Abstracts. Vol. 106. n.º 11 (2005). pp. 5007-.  
 
SCOTT, G. K., [et al.] - Rapid alteration of microRNA levels by histone deacetylase inhibition. 
Cancer Res. Vol. 66. n.º 3 (2006). pp. 1277-81.  
 
SHEEDY, F. J., [et al.] - Negative regulation of TLR4 via targeting of the proinflammatory tumor 
suppressor PDCD4 by the microRNA miR-21. Nat Immunol. Vol. 11. n.º 2 (2010). pp. 141-7.  
 
SHENOUDA, S. K.; ALAHARI, S. K. - MicroRNA function in cancer: oncogene or a tumor 
suppressor? Cancer Metastasis Rev. Vol. 28. n.º 3-4 (2009). pp. 369-78.  
 
SINGH, P. K.; CAMPBELL, M. J. - The Interactions of microRNA and Epigenetic Modifications in 
Prostate Cancer. Cancers (Basel). Vol. 5. n.º 3 (2013). pp. 998-1019.  
 
STEELE, A. J., [et al.] - The sesquiterpene lactone parthenolide induces selective apoptosis of B-
chronic lymphocytic leukemia cells in vitro. Leukemia. Vol. 20. n.º 6 (2006). pp. 1073-9.  
 
TALOTTA, F., [et al.] - An autoregulatory loop mediated by miR-21 and PDCD4 controls the AP-1 
activity in RAS transformation. Oncogene. Vol. 28. n.º 1 (2009). pp. 73-84.  
 
TEIXEIRA, Hugo Lima Pereira Seca - Increasing Sensitivity to Drugs in Leukemias by Modulations of 
MicroRNAs Expression. University of Porto, Faculty of Pharmacy of the University of Porto, 
2013.  
TENG, G.; PAPAVASILIOU, F. N. - Shhh! Silencing by microRNA-155. Philos Trans R Soc Lond B 
Biol Sci. Vol. 364. n.º 1517 (2009). pp. 631-7.  
 
TILI, E.; CROCE, C. M.; MICHAILLE, J. J. - miR-155: on the crosstalk between inflammation and 
cancer. Int Rev Immunol. Vol. 28. n.º 5 (2009). pp. 264-84.  
 
TILI, E., [et al.] - Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha 
stimulation and their possible roles in regulating the response to endotoxin shock. J 
Immunol. Vol. 179. n.º 8 (2007). pp. 5082-9. 
 
TILI, E., [et al.] - The down-regulation of miR-125b in chronic lymphocytic leukemias leads to 
metabolic adaptation of cells to a transformed state. Blood. Vol. 120. n.º 13 (2012). pp. 2631-
8.  
 
TUCCOLI, A.; POLISENO, L.; RAINALDI, G. - miRNAs regulate miRNAs: coordinated 
transcriptional and post-transcriptional regulation. Cell Cycle. Vol. 5. n.º 21 (2006). pp. 2473-
6.  
VARELA-REY, M., [et al.] - Alcohol, DNA methylation, and cancer. Alcohol Res. Vol. 35. n.º 1 (2013). 
pp. 25-35.  
VASILATOU, D., [et al.] - The role of microRNAs in normal and malignant hematopoiesis. Eur J 
Haematol. Vol. 84. n.º 1 (2010). pp. 1-16.  
Reference 
- 71 - 
 
WANG, D., [et al.] - Human microRNA oncogenes and tumor suppressors show significantly 
different biological patterns: from functions to targets. PLoS One. Vol. 5. n.º 9 (2010).  
WEINBERG, R.A. - The Biology of Cancer. Garland Science, 2007.Cap. 11. 9780815340768 
WILSON, A. S.; POWER, B. E.; MOLLOY, P. L. - DNA hypomethylation and human diseases. 
Biochim Biophys Acta. Vol. 1775. n.º 1 (2007). pp. 138-62.  
WINTER, J., [et al.] - Many roads to maturity: microRNA biogenesis pathways and their regulation. 
Nat Cell Biol. Vol. 11. n.º 3 (2009). pp. 228-34.  
WYSOCKA, Joanna; MILNE, Thomas A.; ALLIS, C. David - Taking LSD1 to a New High. Cell. Vol. 
122. n.º 5 (2005). pp. 654-658.  
YOUNG, M. R., [et al.] - Have tumor suppressor PDCD4 and its counteragent oncogenic miR-21 
gone rogue? Mol Interv. Vol. 10. n.º 2 (2010). pp. 76-9.  
ZAKHARI, S. - Alcohol metabolism and epigenetics changes. Alcohol Res. Vol. 35. n.º 1 (2013). pp. 6-
16.  
ZANG, Y. S., [et al.] - MiR-155 inhibits the sensitivity of lung cancer cells to cisplatin via negative 
regulation of Apaf-1 expression. Cancer Gene Ther. Vol. 19. n.º 11 (2012). pp. 773-8. 
ZENG, Z., [et al.] - Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in 
AML. Blood. Vol. 109. n.º 8 (2007). pp. 3509-12.  
ZHANG, H. X.; DU, G. H.; ZHANG, J. T. - Assay of mitochondrial functions by resazurin in vitro. 
Acta Pharmacol Sin. Vol. 25. n.º 3 (2004). pp. 385-9.  
ZHOU, L., [et al.] - microRNA125b promotes leukemia cell resistance to daunorubicin by inhibiting 
apoptosis. Mol Med Rep. Vol. 9. n.º 5 (2014). pp. 1909-16.  
ZHOU, M., [et al.] - MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel 
through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol 
Chem. Vol. 285. n.º 28 (2010). pp. 21496-507. 
 
 
 
 
 
 
 
 
 
 
 
References 
- 72 - 
 
 
 
 
 
 
